UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the Month of June 2024
Commission File Number: 001-41421
Alvotech
(Translation of registrant’s name into
English)
9, Rue de Bitbourg,
L-1273 Luxembourg,
Grand Duchy of Luxembourg
(Address of principal
executive office)
Indicate by check mark whether the registrant files or will
file annual reports under cover of Form 20-F or Form 40-F: x Form
20-F o Form 40-F
Indicate by check mark if the registrant is submitting the Form
6-K in paper as permitted by Regulation S-T Rule 101(b)(1): o
Indicate by check mark if the registrant is submitting the Form
6-K in paper as permitted by Regulation S-T Rule 101(b)(7): o
INFORMATION CONTAINED IN THIS REPORT ON FORM
6-K
Entry into Sales Agreement
On
June 14, 2024, Alvotech (the “Company”) entered into an Open Market Sale AgreementSM (the “Sales
Agreement”) with Jefferies LLC (“Jefferies”), pursuant to which the Company may issue and/or sell the Company’s
ordinary shares, $0.01 nominal value per share (the “Ordinary Shares”) having an aggregate offering price of up to
$75 million from time to time, in at-the-market offerings pursuant to which Jefferies will act as sales agent, subscriber and/or
principal. The Company is not obligated to make any sales of Ordinary Shares under the Sales Agreement.
Subject
to the terms and conditions of the Sales Agreement, Jefferies has agreed to use its commercially reasonable efforts, consistent
with its normal sales and trading practices, to sell all of the Ordinary Shares so designated by the Company with respect to which
Jefferies has agreed to act as sales agent subject to, and in accordance with the information specified in, a written notice from
the Company. The sales, if any, of the Ordinary Shares under the Sales Agreement, will be made (i) in privately negotiated transactions
with the consent of the Company or (ii) by any other method permitted by law deemed to be an “at the market offering”
as defined in Rule 415(a)(4) under the Securities Act of 1933, as amended (the “Securities Act”), including block transactions,
sales made directly on the Nasdaq Global Market or sales made into any other existing U.S. trading market of the Ordinary Shares.
The Sales Agreement provides that the commission payable to Jefferies for sales of the Ordinary Shares with respect to which Jefferies
acts as sales agent shall be up to 3.0% of the gross sales price for such Ordinary Shares sold pursuant to the Sales Agreement.
The
Sales Agreement contains customary representations and warranties of the parties and indemnification and contribution provisions
pursuant to which the Company and Jefferies have agreed to indemnify each other against certain liabilities, including liabilities
under the Securities Act. Jefferies and the Company have the right, by giving written notice as specified in the Sales Agreement,
to terminate the Sales Agreement.
The
foregoing description of the Sales Agreement is not complete and is qualified in its entirety by reference to the full text of
the Sales Agreement, a copy of which is filed as Exhibit 1.1 hereto and is incorporated by reference herein.
The
issuance and sale of the Ordinary Shares pursuant to the Sales Agreement, if any, will be made pursuant to the Company’s
shelf registration statement on Form F-3 (File No. 333-275111), as supplemented by the prospectus supplement (the “Prospectus
Supplement”) dated June 14, 2024.
An
updated summary description of the Company’s business under the headings “Company Overview” and “Recent
Developments” in the section titled “Prospectus Supplement Summary” of the Prospectus Supplement, as well as
certain unaudited financial results for the First Three Months of 2024, are contained in Exhibit 99.1 hereto and is incorporated
by reference herein.
A
copy of the opinion of Arendt & Medernach SA relating to the validity of the securities to be issued pursuant to the Sales
Agreement is filed herewith as Exhibit 5.1 hereto.
This
Report on Form 6-K shall not constitute an offer to sell or solicitation of an offer to buy these securities, nor shall there be
any sale of these securities in any state in which such offer, solicitation or sale would be unlawful prior to registration or
qualification under the securities law of such state or jurisdiction.
Appointment of Mr. Hjörleifur Pálsson
as Director
On
June 7, 2024, the Annual and Extraordinary General Meeting of the Company (the “2024 AGM”) voted to elect Mr. Hjörleifur
Pálsson as an additional director of the Company, effective June 7, 2024. Mr. Pálsson will serve for a term expiring
at the Company’s annual general meeting approving the annual accounts for the financial year ending on December 31, 2024,
or until his earlier death, resignation or removal. Mr. Pálsson will also serve as a member of the Audit committee of the
Board of directors.
Mr.
Pálsson, age 60, has served as non-executive board member in sectors like pharmaceuticals, retail, medical device, media & telecommunications, educational and venture capital. Among other positions, he currently serves as an independent member
of the audit committee of Landsbankinn hf. since May 2019, as a non-executive director of Brunnur vaxtarsj. slhf. since February
2015, and as a non-executive director and chairman of the remuneration committee of Festi hf.. since July 2022. He has previously
served as a non-executive director and chairman of the audit committee of Lotus Pharmaceuticals Co., Ltd. between April 2015 and
June 2024. Mr. Pálsson has also served as a member of the board of directors and board of trustees of Reykjavik University between
June 2010 and July 2022, of which he was the chairman between July 2014 and July 2022. Prior to becoming a board
member, Mr. Pálsson
served as EVP and Chief Financial Officer at Össur hf. between 2001 and 2013, and as partner and public accountant at Deloitte & Touche hf. between 1998 and 2001. Mr. Pálsson holds a Cand oecon degree in Finance and accounting from University
of Iceland.
There
are no arrangements or understandings between Mr. Pálsson and any other persons pursuant to which he was selected as a director.
There is no family relationship between Mr. Pálsson and any of the Company’s other directors or executive officers.
Since January 1, 2023, Mr. Pálsson did not have any direct or indirect material interest in any transaction required to
be disclosed.
Termination of the Standby Equity Purchase
Agreement
On June
11, 2024, the Company provided notice to YA II PN, Ltd. (“Yorkville”) of termination of the Standby Equity Purchase
Agreement dated as of April 18, 2022 by and between the Company and Yorkville.
Cautionary note on forward-looking statements
This Report contains forward-looking statements
within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “may,” “will,”
“expect,” “plan,” “anticipate,” “estimate,” “intend” and similar expressions
(as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking
statements. These forward-looking statements are based on the Company’s expectations and assumptions as of the date of this
Report. Each of these forward-looking statements involves risks and uncertainties. Actual results may differ materially from those
expressed or implied by these forward-looking statements. For a discussion of risk factors that may cause the Company’s actual
results to differ from those expressed or implied in the forward-looking statements in this Report, you should refer to the Company’s
filings with the U.S. Securities and Exchange Commission, including the “Risk Factors” sections contained therein.
Except as required by law, the Company undertakes no obligation to publicly update any forward-looking statements, whether as a
result of new information, future events or otherwise, except as required by law. You should, therefore, not rely on these forward-looking
statements as representing the Company’s views as of any date subsequent to the date of this Report.
Incorporation by Reference
This Report on Form 6-K
(the “Report”), including all Exhibits hereto, shall be deemed to be incorporated by reference into the Company’s
registration statement on Form F-3 (File No. 333-275111), including any prospectuses forming a part thereof, and to be a part thereof
from the date on which this Report is filed, to the extent not superseded by documents or reports subsequently filed or furnished.
This Report, including
Exhibit 99.1, but excluding Exhibits 1.1, 5.1, and 23.1 hereto, shall be deemed to be incorporated by reference into the Company’s
registration statements on Form F-3 (File Nos. 333-266136 and 333-273262) and the Company’s registration statement on Form
S-8 (File No. 333-266881), including any prospectuses forming a part of such registration statements, and to be a part thereof
from the date on which this Report is filed, to the extent not superseded by documents or reports subsequently filed or furnished.
EXHIBIT INDEX
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| |
|
ALVOTECH |
| |
|
|
|
| Date: June 14, 2024 |
|
By: |
/s/ Tanya Zharov |
| |
|
|
Name: |
Tanya Zharov |
| |
|
|
Title: |
General Counsel |
Exhibit 1.1
OPEN
MARKET SALE AGREEMENTSM
June 14,
2024
JEFFERIES LLC
520 Madison Avenue
New York, New York 10022
Ladies and Gentlemen:
Alvotech,
a public limited liability company (société anonyme) incorporated and existing under the laws of the Grand
Duchy of Luxembourg (“Luxembourg”), having its registered office at 9, rue de Bitbourg, L-1273 Luxembourg,
and registered with the Luxembourg Register of Commerce and Companies (R.C.S. Luxembourg) under number B258884 (the
“Company”), proposes, subject to the terms and conditions stated herein, to issue and/or sell from time to
time through Jefferies LLC, as sales agent, subscriber and/or principal (the “Agent”), the Company’s
ordinary shares, $0.01 nominal value (valeur nominale) per share (the “Ordinary Shares”) on the terms set forth
in this agreement (this “Agreement”).
Section 1. DEFINITIONS
(a) Certain
Definitions. For purposes of this Agreement, capitalized terms used herein and not otherwise defined shall have the following
respective meanings:
“Affiliate”
of a Person means another Person that directly or indirectly, through one or more intermediaries, controls, is controlled by, or
is under common control with, such first-mentioned Person. The term “control” (including the terms “controlling,”
“controlled by” and “under common control with”) means the possession, direct or indirect, of the power
to direct or cause the direction of the management and policies of a Person, whether through the ownership of voting securities,
by contract or otherwise.
“Agency Period”
means the period commencing on the date of this Agreement and expiring on the earliest to occur of (x) the date on which the Agent
shall have placed the Maximum Program Amount pursuant to this Agreement and (y) the date this Agreement is terminated pursuant
to Section 7.
SM
“Open Market Sale Agreement” is a service mark of Jefferies LLC
“Bank Account”
means the bank account of the Company to which the Sale Price is payable prior to issuance of the shares in case of New Shares.
“Commission”
means the U.S. Securities and Exchange Commission.
“EU Market
Abuse Regulation” means Regulation (EU) No 596/2014 of the European Parliament and of the Council of 16 April 2014 on
market abuse, as amended.
“EU Prospectus
Regulation” means Regulation (EU) 2017/1129 of the European Parliament and of the Council of 14 June 2017 on the prospectus
to be published when securities are offered to the public or admitted to trading on a regulated market, as amended.
“Exchange Act”
means the Securities Exchange Act of 1934, as amended, and the rules and regulations of the Commission thereunder.
“Floor Price”
means the minimum price set by the Company in the Issuance Notice below which the Agent shall not sell Shares during the applicable
period set forth in the Issuance Notice, which may be adjusted by the Company at any time during the period set forth in the Issuance
Notice by delivering written notice of such change to the Agent and which in no event shall be less than $1.00 without the prior
written consent of the Agent, which may be withheld in the Agent’s sole discretion.
“Issuance Amount”
means the aggregate Sales Price of the Shares to be sold by the Agent pursuant to any Issuance Notice.
“Issuance Notice”
means a written notice delivered to the Agent by the Company in accordance with this Agreement in the form attached hereto as Exhibit
A that is executed by its Chief Executive Officer, President, Chief Financial Officer
or a director and authorized signatory.
“Issuance Notice
Date” means any Trading Day during the Agency Period that an Issuance Notice is delivered
pursuant to Section 3(b)(i).
“Maximum Program
Amount” means Ordinary Shares with an aggregate Sales Price of the lesser of (a) the number or dollar amount of Ordinary
Shares registered under the effective Registration Statement (defined below) pursuant to which the offering is being made, (b)
the number of authorized but unissued Ordinary Shares (less Ordinary Shares issuable upon exercise, conversion or exchange of any
outstanding securities of the Company or otherwise reserved from the Company’s authorized share capital (capital autorisé)),
(c) the number or dollar amount of Ordinary Shares permitted to be sold under Form F-3 (including General Instruction I.B.6 thereof,
if applicable) or, (d) the number or dollar amount of Ordinary Shares for which the Company has filed a Prospectus (defined below).
“New Shares”
means newly issued Ordinary Shares in accordance with the terms of this Agreement.
“Nominal Price”
means the aggregate nominal value of the Shares placed by the Agent pursuant to this Agreement.
“Person”
means an individual or a corporation, partnership, limited liability company, trust, incorporated or unincorporated association,
joint venture, joint stock company, governmental authority or other entity of any kind.
“Placement
Date” means each Trading Day during the period set forth in the Issuance Notice on which Shares are placed pursuant to
this Agreement, when the Agent shall deliver to the Company the Nominal Price of such Shares.
“Principal
Market” means the Nasdaq Global Market or such other U.S. national securities exchange on which the Ordinary Shares,
including any Shares, are then listed.
“Sales Price”
means the actual sale execution price of each Share placed by the Agent pursuant to this Agreement.
“Securities
Act” means the Securities Act of 1933, as amended, and the rules and regulations of the Commission thereunder.
“Selling Commission”
means three percent (3.0%) of the gross proceeds of Shares sold pursuant to this Agreement, or as otherwise agreed between the
Company and the Agent with respect to any Shares sold pursuant to this Agreement.
“Settlement
Date” means the business day immediately following each Placement Date, when the Company shall deliver to the Agent
the amount of Shares placed on such Trading Day and the Agent shall contribute to the equity of the Company without issuing new
shares (account 115 of the standard chart of accounts “apport en capitaux propres non rémunérés
par des titres”) the Settlement Price received on such sales.
“Settlement
Price” means the Sales Price less the Nominal Price.
“Shares”
means (i) any New Shares issued or issuable pursuant to this Agreement and (ii) any Treasury Shares sold pursuant to this Agreement.
“Subscription
Notice” shall mean a written notice delivered to the Company by the Agent in accordance with this Agreement in the form
attached hereto as Exhibit B confirming the subscription of New Shares.
“Trading Day”
means any day on which the Principal Market is open for trading.
“Treasury Shares”
means the Ordinary Shares held by the Company and/or an Affiliate from time to time and sold in accordance
with the terms of this Agreement.
Section 2. REPRESENTATIONS AND WARRANTIES
OF THE COMPANY
The Company represents
and warrants to, and agrees with, the Agent that as of (1) the date of this Agreement, (2) each Issuance Notice Date, (3) each
Settlement Date, (4) each Triggering Event Date (defined below) on which a certificate under Section 4(o) is delivered and (5)
as of each Time of Sale (defined below) (each of the times referenced above is referred to herein as a
“Representation
Date”), except as may be disclosed in the Prospectus (including any documents incorporated by reference therein and any
supplements thereto) on or before a Representation Date:
(a) Registration
Statement. The Company has prepared and filed with the Commission a shelf registration statement on Form F-3 (File No. 333-275111)
that contains a base prospectus (the “Base Prospectus”) that has been declared effective by the Commission.
Such registration statement registers the issuance and sale by the Company of the Shares under the Securities Act. The Company
may file one or more additional registration statements from time to time that will contain a base prospectus and related prospectus
or prospectus supplement, if applicable, with respect to the Shares. Except where the context otherwise requires, such registration
statement(s), including any information deemed to be a part thereof pursuant to Rule 430B under the Securities Act, including all
financial statements, exhibits and schedules thereto and all documents incorporated or deemed to be incorporated therein by reference
pursuant to Item 6 of Form F-3 under the Securities Act as from time to time amended or supplemented, is herein referred to as
the “Registration Statement,” and the prospectus constituting a part of such registration statement(s), together
with any prospectus supplement filed with the Commission pursuant to Rule 424(b) under the Securities Act relating to a particular
issuance of the Shares, including all documents incorporated or deemed to be incorporated therein by reference pursuant to Item
6 of Form F-3 under the Securities Act, in each case, as from time to time amended or supplemented, is referred to herein as the
“Prospectus,” except that if any revised prospectus is provided to the Agent by the Company for use in connection
with the offering of the Shares that is not required to be filed by the Company pursuant to Rule 424(b) under the Securities Act,
the term “Prospectus” shall refer to such revised prospectus from and after the time it is first provided to
the Agent for such use. The Registration Statement at the time it originally became effective is herein called the “Original
Registration Statement.” As used in this Agreement, the terms “amendment” or “supplement” when
applied to the Registration Statement or the Prospectus shall be deemed to include the filing by the Company with the Commission
of any document under the Exchange Act after the date hereof that is or is deemed to be incorporated therein by reference.
All references in this
Agreement to financial statements and schedules and other information which is “contained,” “included”
or “stated” in the Registration Statement or the Prospectus (and all other references of like import) shall be deemed
to mean and include all such financial statements and schedules and other information which is or is deemed to be incorporated
by reference in or otherwise deemed under the Securities Act to be a part of or included in the Registration Statement or the Prospectus,
as the case may be, as of any specified date; and all references in this Agreement to amendments or supplements to the Registration
Statement or the Prospectus shall be deemed to mean and include, without limitation, the filing of any document under the Exchange
Act which is or is deemed to be incorporated by reference in or otherwise deemed under the Securities Act to be a part of or included
in the Registration Statement or the Prospectus, as the case may be, as of any specified date.
At the time the Registration
Statement was originally declared effective and at the time the Company’s most recent annual report on Form 20-F was filed
with the Commission, if later, the Company met the then-applicable requirements for use of Form F-3 under the Securities Act. During
the Agency Period, each time the Company files an annual report on Form 20-F (or Form 10-K if applicable) the Company will meet
the then-applicable requirements for use of Form F-3 (or Form S-3 if applicable) under the Securities Act.
(b)
Compliance with Registration Requirements. The Original Registration Statement and any Rule 462(b) Registration Statement
will have been declared effective by the Commission under the Securities Act prior to the first Issuance Notice. The Company will
comply to the Commission’s satisfaction with all requests of the Commission for additional or supplemental information. No
stop order suspending the effectiveness of the Registration Statement or any Rule 462(b) Registration Statement is in effect and
no proceedings for such purpose have been instituted or are pending or, to the knowledge of the Company, are contemplated or threatened
by the Commission.
The Prospectus when
filed complied or will comply in all material respects with the Securities Act and, if filed with the Commission through its Electronic
Data Gathering, Analysis and Retrieval system (“EDGAR”) (except as may be permitted by Regulation S-T under
the Securities Act), was or will be identical to the copy thereof delivered to the Agent for use in connection with the issuance
and sale of the Shares. Each of the Registration Statement, any Rule 462(b) Registration Statement and any post-effective amendment
thereto, at the time it became effective and at each Representation Date, complied and will comply in all material respects with
the Securities Act and did not and will not contain any untrue statement of a material fact or omit to state a material fact required
to be stated therein or necessary to make the statements therein not misleading. As of the date of this Agreement, the Prospectus
and any Free Writing Prospectus (defined below) considered together (collectively, the “Time of Sale Information”)
did not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements therein,
in the light of the circumstances under which they were made, not misleading. The Prospectus, as amended or supplemented, as of
its date and at each Representation Date, did not and will not contain any untrue statement of a material fact or omit to state
a material fact necessary in order to make the statements therein, in the light of the circumstances under which they were made,
not misleading. The representations and warranties set forth in the three immediately preceding sentences do not apply to statements
in or omissions from the Registration Statement, any Rule 462(b) Registration Statement, or any post-effective amendment thereto,
or the Prospectus, or any amendments or supplements thereto, made in reliance upon and in conformity with information relating
to the Agent furnished to the Company in writing by the Agent expressly for use therein, it being understood and agreed that the
only such information furnished by the Agent to the Company consists of the information described in Section 6 below. There
are no contracts or other documents required to be described in the Prospectus or to be filed as exhibits to the Registration Statement
which have not been described or filed as required. The Registration Statement and the offer and sale of the Shares as contemplated
hereby meet the requirements of Rule 415 under the Securities Act and comply in all material respects with said rule.
(c)
Incorporated Documents. The documents incorporated or deemed to be incorporated by reference in the Registration
Statement and the Prospectus, at the time they were filed with the Commission, complied in all material respects with the requirements
of the Exchange Act, as applicable, and, when read together with the other information in the Prospectus at the time the Registration
Statement and any amendments thereto become effective and at each Time of Sale (defined below), as the case may be, did not or
will not contain an untrue statement of a material fact or omit to state a material fact required to be stated therein or necessary
to make the statements therein, in light of the circumstances under which they were made, not misleading.
(d)
Exchange Act Compliance. The documents incorporated or deemed to be incorporated by reference in the Prospectus,
at the time they were or hereafter are filed with the Commission, and any Free Writing Prospectus or amendment or supplement thereto
complied and will comply in all material respects with the requirements of the Exchange Act, and, when read together with the other
information in the Prospectus, at the time the Registration Statement and any amendments thereto become effective and at each Time
of Sale (defined below), as the case may be, will not contain an untrue statement of a material fact or omit to state a material
fact required to be stated therein or necessary to make the fact required to be stated therein or necessary to make the statements
therein, in the light of the circumstances under which they were made, not misleading.
(e)
Statistical and Market-Related Data. All statistical, demographic and market-related data included in the Registration
Statement or the Prospectus are based on or derived from sources that the Company believes, after reasonable inquiry, to be reliable
and accurate. To the extent required, the Company has obtained the written consent for the use of such data from such sources.
(f)
Disclosure Controls and Procedures; Deficiencies in or Changes to Internal Control Over Financial Reporting. The
Company has established and maintains disclosure controls and procedures (as defined in Rules 13a-15 and 15d-15 under the Exchange
Act), which (i) are designed to ensure that material information relating to the Company, including its consolidated subsidiaries,
is made known to the Company’s principal executive officer and its principal financial officer by others within those entities,
particularly during the periods in which the periodic reports required under the Exchange Act are being prepared; (ii) have been
evaluated by management of the Company for effectiveness as of the end of the Company’s most recent fiscal year; and (iii)
except as disclosed in the Registration Statement and the Prospectus, are effective in all material respects to perform the functions
for which they were established. Except as disclosed in the Registration Statement and the Prospectus, since the end of the Company’s
most recent audited fiscal year, there have been no significant deficiencies or material weaknesses in the Company’s internal
control over financial reporting (whether or not remediated) and no change in the Company’s internal control over financial
reporting that has materially affected, or is reasonably likely to materially affect, the Company’s internal control over
financial reporting. The Company is not aware of any change in its internal control over financial reporting that has occurred
since the end of the Company’s most recent audited fiscal year that has materially affected, or is reasonably likely to materially
affect, the Company’s internal control over financial reporting.
(g)
This Agreement. This Agreement has been duly authorized, executed and delivered by the Company.
(h)
Authorization of the Shares. The Shares, when issued and delivered by the Company against full payment therefor pursuant
to this Agreement, will be validly issued, fully paid and nonassessable (meaning that the holder of such Shares shall not be liable,
solely because of its shareholder status, for additional payments to the Company or the Company’s creditors), and the issuance
and/or sale of the Shares will not be subject to any preemptive rights, rights of first refusal or other similar rights to subscribe
for or purchase the Shares.
(i)
No Applicable Registration or Other Similar Rights. There are no persons with registration or other similar rights
to have any equity or debt securities registered for sale under the Registration Statement or included in the offering contemplated
by this Agreement, except for such rights as have been duly waived.
(j)
No Material Adverse Change. Except as otherwise disclosed in the Registration Statement
and the Prospectus, subsequent to the respective dates as of which information is given in the Registration Statement and the Prospectus:
(i) there has been no material adverse change, or any development that could be expected to result in a material adverse change,
in (A) the condition, financial or otherwise, or in the earnings, business, properties, operations, operating results, assets,
liabilities or prospects, whether or not arising from transactions in the ordinary course of business, of the Company and its subsidiaries,
considered as one entity or (B) the ability of the Company to consummate the transactions contemplated by this Agreement or perform
its obligations hereunder (any such change being referred to herein as a “Material Adverse Change”); (ii) the
Company and its subsidiaries, considered as one entity, have not incurred any material liability or obligation, indirect, direct
or contingent, including without limitation any losses or interference with their business from fire, explosion, flood, earthquakes,
accident or other calamity, whether or not covered by insurance, or from any strike, labor dispute or court or governmental action,
order or decree, that are material, individually or in the aggregate, to the Company and its subsidiaries, considered as one entity,
and have not entered into any transactions not in the ordinary course of business; and (iii) there has not been any material decrease
in the share capital or any material increase in any short-term or long-term indebtedness of the Company or its subsidiaries and
there has been no dividend or distribution of any kind declared, paid or made by the Company or, except for dividends paid to the
Company or other subsidiaries, by any of the Company’s subsidiaries on any class of share capital, or any repurchase or redemption
by the Company or any of its subsidiaries of any class of share capital.
(k)
Independent Accountants. Deloitte ehf., which has expressed its opinion with respect to the financial statements
(which term as used in this Agreement includes the related notes thereto) filed with the Commission as a part of the Registration
Statement and the Prospectus, is (i) an independent registered public accounting firm as required by the Exchange Act, and the
rules of the Public Company Accounting Oversight Board (“PCAOB”), (ii) in compliance with the applicable requirements
relating to the qualification of accountants under Rule 2-01 of Regulation S-X under the Securities Act and (iii) a registered
public accounting firm as defined by the PCAOB whose registration has not been suspended or revoked and who has not requested such
registration to be withdrawn.
(l)
Financial Statements. The financial statements filed with the Commission as a part of the Registration Statement
and the Prospectus present fairly the consolidated financial position of the Company and its subsidiaries as of the dates indicated
and the results of their operations, changes in shareholders’ equity and cash flows for the periods specified. Such financial
statements have been prepared in conformity with generally accepted accounting principles as applied by the International Financial
Reporting Standards (“IFRS”) as adopted by the International Accounting Standards Board applied on a consistent
basis throughout the periods involved, except as may be expressly stated in the related notes thereto. The interactive data in
eXtensible Business Reporting Language included or incorporated by reference in the Registration Statement fairly presents the
information called for in all material respects and has been prepared in accordance with the
Commission’s rules
and guidelines applicable thereto. No other financial statements or supporting schedules are required to be included in the Registration
Statement or the Prospectus. The financial data set forth in each of the Registration Statement and the Prospectus fairly present
in all material respects the information set forth therein on a basis consistent with that of the audited financial statements
contained in the Registration Statement and the Prospectus. To the Company’s knowledge, no person who has been suspended
or barred from being associated with a registered public accounting firm, or who has failed to comply with any sanction pursuant
to Rule 5300 promulgated by the PCAOB, has participated in or otherwise aided the preparation of, or audited, the financial statements,
supporting schedules or other financial data filed with the Commission as a part of the Registration Statement and the Prospectus.
(m)
Company’s Accounting System. The Company and each of its subsidiaries make and keep accurate books and records
and maintain a system of internal accounting controls sufficient to provide reasonable assurance that: (i) transactions are executed
in accordance with management’s general or specific authorization; (ii) transactions are recorded as necessary to permit
preparation of financial statements in conformity with IFRS as adopted by the International Accounting Standards Board and to maintain
accountability for assets; (iii) access to assets is permitted only in accordance with management’s general or specific authorization;
(iv) the recorded accountability for assets is compared with existing assets at reasonable intervals and appropriate action is
taken with respect to any differences; and (v) the interactive data in eXtensible Business Reporting Language included or incorporated
by reference in the Registration Statement and the Prospectus fairly presents the information called for in all material respects
and is prepared in accordance with the Commission’s rules and guidelines applicable thereto.
(n)
Incorporation of the Company. The Company has been duly incorporated and is existing as a public limited liability
company (société anonyme) under the laws of the Grand Duchy of Luxembourg and has the corporate power and
authority to own, lease and operate its properties and to conduct its business as described in the Registration Statement and the
Prospectus and to enter into and perform its obligations under this Agreement. The Company is duly qualified as a foreign corporation
to transact business in each other jurisdiction in which such qualification is required, whether by reason of the ownership or
leasing of property or the conduct of business.
(o) Subsidiaries.
Each of the Company’s “subsidiaries” (for purposes of this Agreement, as defined in Rule 405 under the
Securities Act) has been duly incorporated or organized, as the case may be, and is validly existing as a corporation,
partnership or limited liability company, as applicable, in good standing (where such concept is recognized under the laws of
the jurisdiction in which they are organized and formed) under the laws of the jurisdiction of its incorporation
or organization and has the power and authority (corporate or other) to own, lease and operate its properties and to conduct
its business as described in the Registration Statement and the Prospectus. Each of the Company’s subsidiaries is duly
qualified as a foreign corporation, partnership or limited liability company, as applicable, to transact business and is in
good standing (where such concept is recognized under the laws of the jurisdiction in which they are organized and formed) in
each jurisdiction in which such qualification is required, whether by reason of the ownership or leasing of property or the
conduct of business. All of the issued and outstanding share capital or other equity or ownership interests of each of the
Company’s subsidiaries have been duly authorized and validly issued, are fully paid and nonassessable (meaning that the
holder of such Shares shall not be liable, solely because of its shareholder status,
for additional payments
to the Company or the Company’s creditors) and, except as disclosed in the Registration Statement and the Prospectus, all
such shares are owned by the Company, directly or through subsidiaries, free and clear of any security interest, mortgage, pledge,
lien, encumbrance or adverse claim. None of the outstanding share capital or equity interest in any subsidiary was issued in violation
of preemptive or similar rights of any security holder of such subsidiary. The constitutive or organizational documents of each
of the subsidiaries comply in all material respects with the requirements of applicable laws of its jurisdiction of incorporation
or organization and are in full force and effect. All of the Company’s “significant subsidiaries” as defined
Regulation S-X 1-02(w) of the Exchange Act are listed on Exhibit 8.1 to the Company’s Annual Report on Form 20-F for the
most fiscal year ended.
(p) Capitalization
and Other Share Capital Matters. The share capital of the Company is as set forth in the Registration Statement and the Prospectus
under the caption “Description of Share Capital and Articles of Association” (other than for subsequent issuances,
if any, pursuant to employee benefit plans described in the Prospectus, upon the exercise of outstanding options or warrants or
such other equity issuances as described in the Registration Statement and the Prospectus). The Ordinary Shares (including the
Shares) conform in all material respects to the description thereof contained in the Prospectus. All of the issued and outstanding
Ordinary Shares have been validly issued, are fully paid and nonassessable (meaning that the holder of such Shares shall not be
liable, solely because of its shareholder status, for additional payments to the Company or the Company’s creditors) and
have been issued in compliance with the laws of the Grand Duchy of Luxembourg and, to the extent applicable, with all federal and
state securities laws. None of the Ordinary Shares was issued in violation of any preemptive rights, rights of first refusal or
other similar rights to subscribe for or purchase securities of the Company. There are no authorized or outstanding options, warrants,
preemptive rights, rights of first refusal or other rights to purchase, or equity or debt securities convertible into or exchangeable
or exercisable for, any share capital of the Company or any of its subsidiaries other than those described in the Registration
Statement and the Prospectus. The descriptions of the Company’s stock option, stock bonus and other equity plans or arrangements,
and the options or other rights granted thereunder, set forth in the Registration Statement and the Prospectus accurately and fairly
presents the information required to be shown with respect to such plans, arrangements, options and rights.
(q) Stock
Exchange Listing. The Ordinary Shares are registered pursuant to Section 12(b) or 12(g) of the Exchange Act and are listed
on the Principal Market, and the Company has taken no action designed to, or likely to have the effect of, terminating the registration
of the Ordinary Shares under the Exchange Act or delisting the Ordinary Shares from the Principal Market, nor has the Company received
any notification that the Commission or the Principal Market is contemplating terminating or suspending such registration or listing.
To the Company’s knowledge, it is in compliance with all applicable listing requirements of the Principal Market.
(r) Non-Contravention
of Existing Instruments; No Further Authorizations or Approvals Required. Neither the Company nor any of its subsidiaries is
in violation of its articles of association, charter or by-laws, partnership agreement or operating agreement or similar organizational
documents, as applicable, or is in default (or, with the giving of notice or lapse of time, would be in default) (“Default”)
under any indenture, loan, credit agreement, note, lease, license agreement, contract, franchise or other instrument (including,
without limitation, any pledge agreement, security agreement, mortgage or other instrument or agreement evidencing,
guaranteeing, securing
or relating to indebtedness) to which the Company or any of its subsidiaries is a party or by which it or any of them may be bound,
or to which any of their respective properties or assets are subject (each, an “Existing Instrument”), except
for such Defaults as could not be expected, individually or in the aggregate, to result in a Material Adverse Change. The Company’s
execution, delivery and performance of this Agreement, consummation of the transactions contemplated hereby and by the Registration
Statement and the Prospectus and the issuance and sale of the Shares (including the use of proceeds from the sale of the Shares
as described in the Registration Statement and the Prospectus under the caption “Use of Proceeds”) (i) have been duly
authorized by all necessary corporate action and will not result in any violation of the provisions of the articles of association,
charter or by-laws, partnership agreement or operating agreement or similar organizational documents, as applicable, of the Company
or any subsidiary (ii) will not conflict with or constitute a breach of, or Default or a Debt Repayment Triggering Event (defined
below) under, or result in the creation or imposition of any lien, charge or encumbrance upon any property or assets of the Company
or any of its subsidiaries pursuant to, or require the consent of any other party to, any Existing Instrument, except as could
not be expected, individually or in the aggregate, to result in a Material Adverse Change, and (iii) will not result in any violation
of any law, administrative regulation or administrative or court decree applicable to the Company or any of its subsidiaries. No
consent, approval, authorization or other order of, or registration or filing with, any court or other governmental or regulatory
authority or agency, is required for the Company’s execution, delivery and performance of this Agreement and consummation
of the transactions contemplated hereby and by the Registration Statement and the Prospectus, except such as have been obtained
or made by the Company and are in full force and effect under the Securities Act and such as may be required under applicable state
securities or blue sky laws or FINRA (defined below). As used herein, a “Debt Repayment Triggering Event” means
any event or condition which gives, or with the giving of notice or lapse of time would give, the holder of any note, debenture
or other evidence of indebtedness (or any person acting on such holder’s behalf) the right to require the repurchase, redemption
or repayment of all or a portion of such indebtedness by the Company or any of its subsidiaries.
(s) No
Material Actions or Proceedings. Except as otherwise disclosed in the Prospectus, there is no action, suit or proceeding, or
written notice of inquiry or investigation, brought by or before any legal or governmental entity now pending or, to the knowledge
of the Company, threatened, against or affecting the Company or any of its subsidiaries, which could be expected, individually
or in the aggregate, to result in a Material Adverse Change. No material labor dispute with the employees of the Company or any
of its subsidiaries, or with the employees of any principal supplier, manufacturer, customer or contractor of the Company, exists
or, to the knowledge of the Company, is threatened or imminent.
(t) Intellectual
Property Rights. Except as otherwise disclosed in the Registration Statement or the Prospectus, the Company and its subsidiaries
own, or have obtained valid and enforceable licenses for, the inventions, patent applications, patents, trademarks, trade names,
service names, copyrights, trade secrets and other intellectual property described in the Registration Statement and the Prospectus
as being owned or licensed by them or which are necessary for the conduct of their respective businesses as currently conducted
or as currently proposed to be conducted (collectively, “Intellectual Property”) and the conduct of their respective
businesses does not and will not infringe, misappropriate or otherwise conflict in any material respect with any such rights of
others. The Intellectual Property of the Company has not
been adjudged by a court
of competent jurisdiction to be invalid or unenforceable, in whole or in part, and the Company is unaware of any facts which would
form a reasonable basis for any such adjudication. To the Company’s knowledge: (i) there are no third parties who have rights
to any Intellectual Property, except for customary reversionary rights of third-party licensors with respect to Intellectual Property
that is disclosed in the Registration Statement and the Prospectus as licensed to the Company or one or more of its subsidiaries;
and (ii) there is no infringement by third parties of any Intellectual Property. There is no pending or, to the Company’s
knowledge, threatened action, suit, proceeding or claim by others: (A) challenging the Company’s rights in or to any Intellectual
Property, and the Company is unaware of any facts which would form a reasonable basis for any such action, suit, proceeding or
claim; (B) challenging the validity, enforceability or scope of any Intellectual Property, and the Company is unaware of any facts
which would form a reasonable basis for any such action, suit, proceeding or claim; or (C) asserting that the Company or any of
its subsidiaries infringes or otherwise violates, or would, upon the commercialization of any product or service described in the
Registration Statement or the Prospectus as under development, infringe or violate, any patent, trademark, trade name, service
name, copyright, trade secret or other proprietary rights of others, and the Company is unaware of any facts which would form a
reasonable basis for any such action, suit, proceeding or claim. The Company and its subsidiaries have complied with the terms
of each agreement pursuant to which Intellectual Property has been licensed to the Company or any subsidiary, and all such agreements
are in full force and effect. To the Company’s knowledge, there are no material defects in any of the patents or patent applications
included in the Intellectual Property. The Company and its subsidiaries have taken all reasonable steps to protect, maintain and
safeguard their Intellectual Property, including the execution of appropriate nondisclosure, confidentiality agreements and invention
assignment agreements and invention assignments with their employees, and no employee of the Company is in or has been in violation
of any term of any employment contract, patent disclosure agreement, invention assignment agreement, non-competition agreement,
non-solicitation agreement, nondisclosure agreement, or any restrictive covenant to or with a former employer where the basis of
such violation relates to such employee’s employment with the Company. The duty of candor and good faith as required by the
United States Patent and Trademark Office during the prosecution of the United States patents and patent applications included
in the Intellectual Property have been complied with; and in all foreign offices having similar requirements, all such requirements
have been complied with. None of the Company owned Intellectual Property or technology (including information technology and outsourced
arrangements) employed by the Company or its subsidiaries has been obtained or is being used by the Company or its subsidiary in
violation of any contractual obligation binding on the Company or its subsidiaries or any of their respective officers, directors
or employees or otherwise in violation of the rights of any persons. The product candidates described in the Registration Statement
and the Prospectus as under development by the Company or any subsidiary fall within the scope of the claims of one or more patents
owned by, or exclusively licensed to, the Company or any subsidiary.
(u) All
Necessary Permits, etc. Except as otherwise disclosed in the Prospectus, the Company and each subsidiary possess such valid
and current certificates, authorizations or permits required by state, federal or foreign regulatory agencies or bodies to conduct
their respective businesses as currently conducted and as described in the Registration Statement or the Prospectus, except where
the failure to possess such certificates, authorizations or permits would not, individually or in the aggregate, reasonably be
expected to result in a Material Adverse Change (“Permits”). Neither the Company nor any of its subsidiaries
is in violation of, or in default under,
any of the Permits or
has received any notice of proceedings relating to the revocation or modification of, or non-compliance with, any such certificate,
authorization or permit, except as would not, individually or in the aggregate, reasonably be expected to result in a Material
Adverse Change.
(v) Title
to Properties. Except as otherwise disclosed in the Prospectus, the Company and its subsidiaries have good and marketable title
to all of the real and personal property and other assets reflected as owned in the financial statements referred to in Section
2(l) above (or elsewhere in the Registration Statement or the Prospectus, in each case free and clear of any security interests,
mortgages, liens, encumbrances, equities, adverse claims and other defects, except for those that are for the payment of taxes
not yet due and delinquent or for which appropriate reserves have been made therefor. The real property, improvements, equipment
and personal property held under lease by the Company or its subsidiaries are held under valid and enforceable leases, with such
exceptions as are not material and do not materially interfere with the use made or proposed to be made of such real property,
improvements, equipment or personal property by the Company or such subsidiary.
(w) Tax
Law Compliance. The Company and its subsidiaries have filed all U.S. federal, U.S. state and foreign income and franchise tax
returns required to be filed by any of them or have properly requested extensions thereof and have paid all taxes required to be
paid by any of them (except for taxes being contested in good faith and by appropriate proceedings), except as would not, individually
or in the aggregate, reasonably be expected to result in a Material Adverse Change. The Company has made adequate charges, accruals
and reserves in the applicable financial statements referred to in Section 2(l) above in respect of all U.S. federal, U.S.
state and foreign income and franchise taxes for all periods as to which the tax liability of the Company or any of its subsidiaries
has not been finally determined, except for taxes being contested in good faith and by appropriate proceedings or where such inadequacy
would not reasonably be expected to have a Material Adverse Change.
(x) Company
Not an “Investment Company.” The Company is not, and will not be, either after receipt of payment for the Shares
or after the application of the proceeds therefrom as described under “Use of Proceeds” in the Registration Statement
or the Prospectus, required to register as an “investment company” under the Investment Company Act of 1940, as amended
(the “Investment Company Act”).
(y) Insurance.
Except as otherwise disclosed in the Prospectus, each of the Company and its subsidiaries are insured by recognized, financially
sound and reputable institutions with policies in such amounts and with such deductibles and covering such risks as are generally
deemed adequate and customary for their businesses including, but not limited to, policies covering real and personal property
owned or leased by the Company and its subsidiaries against theft, damage, destruction, acts of vandalism and earthquakes and policies
covering the Company and its subsidiaries for product liability claims and clinical trial liability claims. The Company has no
reason to believe that it or any of its subsidiaries will not be able (i) to renew its existing insurance coverage as and when
such policies expire or (ii) to obtain comparable coverage from similar institutions as may be necessary or appropriate to conduct
its business as now conducted and at a cost that could not be expected to result in a Material Adverse Change. Neither the Company
nor
any of its subsidiaries
has been denied any insurance coverage which it has sought or for which it has applied.
(z) No
Price Stabilization or Manipulation; Compliance with Regulation M. Neither the Company nor any of its subsidiaries has taken,
directly or indirectly, any action designed to or that might cause or result in stabilization or manipulation of the price of the
Ordinary Shares or of any “reference security” (as defined in Rule 100 of Regulation M under the Exchange Act (“Regulation
M”)) with respect to the Ordinary Shares, whether to facilitate the sale or resale of the Shares or otherwise, and has
taken no action which would directly or indirectly violate Regulation M.
(aa) Related
Party Transactions. There are no business relationships or related-party transactions involving the Company or any of its subsidiaries
or any other person required to be described in the Registration Statement or the Prospectus which have not been described as required.
(bb) FINRA
Matters. All of the information provided to the Agent or to counsel for the Agent by the Company, its counsel, its officers
and directors and the holders of any securities (debt or equity) or options to acquire any securities of the Company in connection
with the offering of the Shares is true, complete, correct and compliant in all material respects with Financial Industry Regulatory
Authority, Inc.’s (“FINRA”) rules and any letters, filings or other supplemental information provided
to FINRA pursuant to FINRA Rules or NASD Conduct Rules is true, complete and correct.
(cc) No
Unlawful Contributions or Other Payments. Except as otherwise disclosed in the Prospectus, neither the Company nor any of its
subsidiaries nor, to the Company’s knowledge, any employee or agent of the Company or any subsidiary, has made any contribution
or other payment to any official of, or candidate for, any federal, state or foreign office in violation of any law or of the character
required to be disclosed in the Registration Statement and the Prospectus.
(dd) Compliance
with Environmental Laws. Except as described in the Prospectus and except as could not be expected, individually or in the
aggregate, to result in a Material Adverse Change; (i) neither the Company nor any of its subsidiaries is in violation of any federal,
state, local or foreign statute, law, rule, regulation, ordinance, code, policy or rule of common law or any judicial or administrative
interpretation thereof, including any judicial or administrative order, consent, decree or judgment, relating to pollution or protection
of human health, the environment (including, without limitation, ambient air, surface water, groundwater, land surface or subsurface
strata) or wildlife, including, without limitation, laws and regulations relating to the release or threatened release of chemicals,
pollutants, contaminants, wastes, toxic substances, hazardous substances, petroleum or petroleum products (collectively, “Hazardous
Materials”) or to the manufacture, processing, distribution, use, treatment, storage, disposal, transport or handling
of Hazardous Materials (collectively, “Environmental Laws”), (ii) the Company and its subsidiaries have all
permits, authorizations and approvals required under any applicable Environmental Laws and are each in compliance with their requirements,
(iii) there are no pending or threatened administrative, regulatory or judicial actions, suits, demands, demand letters, claims,
liens, notices of noncompliance or violation, investigation or proceedings relating to any Environmental Law against the Company
or any of its subsidiaries and (iv) there are no events or circumstances that
might reasonably be expected
to form the basis of an order for clean-up or remediation, or an action, suit or proceeding by any private party or governmental
body or agency, against or affecting the Company or any of its subsidiaries relating to Hazardous Materials or any Environmental
Laws.
(ee) Brokers.
Except as otherwise disclosed in the Prospectus, there is no broker, finder or other party that is entitled to receive from the
Company any brokerage or finder’s fee or other fee or commission as a result of any transactions contemplated by this Agreement.
(ff) Dividend
Restrictions. Except as disclosed in the Prospectus, no subsidiary of the Company is prohibited or restricted, directly or
indirectly, from paying dividends to the Company, or from making any other distribution with respect to such subsidiary’s
equity securities or from repaying to the Company or any other subsidiary of the Company any amounts that may from time to time
become due under any loans or advances to such subsidiary from the Company or from transferring any property or assets to the Company
or to any other subsidiary.
(gg) Anti-Corruption
and Anti-Bribery Laws. The Company nor any of its subsidiaries nor any director,
officer, or employee of the Company or any of its subsidiaries, nor to the knowledge of the Company, any agent, Affiliate or other
person acting on behalf of the Company or any of its subsidiaries has, in the course of its actions for, or on behalf of, the Company
or any of its subsidiaries (i) used any corporate funds for any unlawful contribution, gift, entertainment or other unlawful expenses
relating to political activity; (ii) made or taken any act in furtherance of an offer, promise, or authorization of any direct
or indirect unlawful payment or benefit to any foreign or domestic government official or employee, including of any government-owned
or controlled entity or public international organization, or any political party, party official, or candidate for political office;
(iii) violated or is in violation of any provision of the U.S. Foreign Corrupt Practices Act of 1977, as amended (the “FCPA”),
the UK Bribery Act 2010, or any other applicable anti-bribery or anti-corruption law; or (iv) made, offered, authorized, requested,
or taken an act in furtherance of any unlawful bribe, rebate, payoff, influence payment, kickback or other unlawful payment or
benefit. The Company and its subsidiaries and the Company’s Affiliates have conducted their respective businesses in compliance
with the FCPA and have instituted and maintain policies and procedures designed to ensure, and which are reasonably expected to
continue to ensure, continued compliance therewith.
(hh) Money
Laundering Laws. The operations of the Company and its subsidiaries are, and have been conducted at all times, in compliance
with applicable financial recordkeeping and reporting requirements of the Currency and Foreign Transactions Reporting Act of 1970,
as amended, the money laundering statutes of all applicable jurisdictions, the rules and regulations thereunder and any related
or similar applicable rules, regulations or guidelines, issued, administered or enforced by any governmental agency (collectively,
the “Money Laundering Laws”) and no action, suit or proceeding by or before any court or governmental agency,
authority or body or any arbitrator involving the Company or any of its subsidiaries with respect to the Money Laundering Laws
is pending or, to the knowledge of the Company, threatened.
(ii) Clinical
Data and Regulatory Compliance. The preclinical tests and clinical trials, and other studies (collectively,
“studies”) that are described in, or the results of which are referred to in, the Registration Statement or
the Prospectus were and, if still pending, are being conducted
in all material respects
in accordance with the applicable laws, protocols, procedures and controls designed and approved for such studies and with standard
medical and scientific research procedures; each description of the results of such studies is accurate and complete in all material
respects and fairly presents the data derived from such studies, and the Company and its subsidiaries have no knowledge of any
other studies the results of which are inconsistent with, or otherwise call into question, the results described or referred to
in the Registration Statement or the Prospectus; the Company and its subsidiaries have made all such filings and obtained all such
approvals as may be required by the Food and Drug Administration of the U.S. Department of Health and Human Services or any committee
thereof or from any other U.S. or foreign government or drug or medical device regulatory agency, or health care facility Institutional
Review Board or Ethics Committee (collectively, the “Regulatory Agencies”); neither the Company nor any of its
subsidiaries has received any notice of, or correspondence from, any Regulatory Agency requiring the termination, suspension or
modification of any clinical trials that are described or referred to in the Registration Statement or the Prospectus; and the
Company and its subsidiaries have each operated and currently are in compliance in all material respects with all applicable rules,
regulations and policies of the Regulatory Agencies.
(jj) Sanctions.
Neither the Company nor any of its subsidiaries, directors, officers, or employees, nor, to the knowledge of the
Company, after due inquiry, any agent, Affiliate or other person acting on behalf of the Company or any of its subsidiaries
is currently the subject or the target of any U.S. sanctions administered by the Office of Foreign Assets Control of the U.S.
Department of the Treasury (“OFAC”) or the U.S. Department of State, the United Nations Security Council,
the European Union, His Majesty’s Treasury of the United Kingdom, or other relevant foreign sanctions authority
(collectively, “Sanctions”); nor is the Company or any of its subsidiaries located, organized or resident
in a country or territory that is the subject or the target of Sanctions, including, without limitation, Zaporizhzhia and
Kherson Regions of Ukraine, the so-called Donetsk People’s Republic, the so-called Luhansk People’s Republic,
Cuba, Iran, North Korea and Syria; and the Company will not directly or indirectly use the proceeds of this offering, or
lend, contribute or otherwise make available such proceeds to any subsidiary, or any joint venture partner or other person or
entity, for the purpose of financing the activities of or business with any person, or in any country or territory, that at
the time of such financing, is the subject or the target of Sanctions in violation of applicable Sanctions, or in any other
manner that will result in a violation by any person (including any person participating in the transaction whether as
underwriter, advisor, investor or otherwise) of applicable Sanctions. Since April 24, 2019, the Company and its
subsidiaries have not knowingly engaged in and are not now knowingly engaged in any dealings or transactions with any person
that at the time of the dealing or transaction is or was the subject or the target of Sanctions or with any Sanctioned
Country in violation of applicable Sanctions.
(kk) Sarbanes-Oxley.
The Company is in compliance, in all material respects, with all applicable provisions of the Sarbanes-Oxley Act of 2002 and the
rules and regulations promulgated thereunder.
(ll) Cybersecurity.
The Company and its subsidiaries’ information technology assets and equipment, computers, systems,
networks, hardware, software, websites, applications, and databases (collectively, “IT Systems”) are adequate
for, and operate and perform in all material respects as required in connection with the operation of the business of the Company
and its
subsidiaries as currently
conducted, free and clear of all material bugs, errors, defects, Trojan horses, time bombs, malware and other corruptants. The
Company and its subsidiaries have implemented and maintained commercially reasonable physical, technical and administrative controls,
policies, procedures, and safeguards to maintain and protect their material confidential information and the integrity, continuous
operation, redundancy and security of all IT Systems and data, including “Personal Data,” used in connection with their
businesses. “Personal Data” means (i) a natural person’s name, street address, telephone number, e-mail
address, photograph, social security number or tax identification number, driver’s license number, passport number, credit
card number, bank information, or customer or account number; (ii) any information which would qualify as “personally identifying
information” under the Federal Trade Commission Act, as amended; (iii) “personal data” as defined by GDPR; (iv)
any information which would qualify as “protected health information” under the Health Insurance Portability and Accountability
Act of 1996, as amended by the Health Information Technology for Economic and Clinical Health Act (collectively, “HIPAA”);
and (v) any other piece of information that allows the identification of such natural person, or his or her family, or permits
the collection or analysis of any data related to an identified person’s health or sexual orientation. There have been no
breaches, violations, outages or unauthorized uses of or accesses to same, except for those that have been remedied without material
cost or liability or the duty to notify any other person, nor any incidents under internal review or investigations relating to
the same. The Company and its subsidiaries are presently in material compliance with all applicable laws or statutes and all judgments,
orders, rules and regulations of any court or arbitrator or governmental or regulatory authority, internal policies and contractual
obligations relating to the privacy and security of IT Systems and Personal Data and to the protection of such IT Systems and Personal
Data from unauthorized use, access, misappropriation or modification.
(mm) Compliance
with Data Privacy Laws. The Company and its subsidiaries are, and at all prior times were, in material compliance with all
applicable state and federal data privacy and security laws and regulations, including without limitation HIPAA, and the Company
and its subsidiaries have taken commercially reasonable actions to prepare to comply with, and since May 25, 2018, have been and
currently are in compliance with, the European Union General Data Protection Regulation (“GDPR”) (EU 2016/679)
(collectively, the “Privacy Laws”). To ensure compliance with the Privacy Laws, the Company and its subsidiaries
have in place, comply with, and take appropriate steps reasonably designed to ensure compliance in all material respects with their
policies and procedures relating to data privacy and security and the collection, storage, use, disclosure, handling, and analysis
of Personal Data (the “Policies”). The Company and its subsidiaries have at all times made all disclosures to
users or customers required by applicable laws and regulatory rules or requirements, and none of such disclosures made or contained
in any Policy have, to the knowledge of the Company, been inaccurate or in violation of any applicable laws and regulatory rules
or requirements in any material respect. The Company further certifies that neither it nor any subsidiary: (i) has received notice
of any actual or potential liability under or relating to, or actual or potential violation of, any of the Privacy Laws, and has
no knowledge of any event or condition that would reasonably be expected to result in any such notice; (ii) is currently conducting
or paying for, in whole or in part, any investigation, remediation, or other corrective action pursuant to any Privacy Law; or
(iii) is a party to any order, decree, or agreement that imposes any obligation or liability under any Privacy Law.
(nn) Other
Underwriting Agreements. Except as otherwise disclosed in the Registration Statement or the Prospectus, the Company is not
a party to any agreement with an agent or underwriter for any other “at the market” or continuous equity transaction.
(oo) Medicare
and Medicaid Programs. To the extent required in connection with their respective businesses, each of the Company and its subsidiaries
has the requisite provider number or other authorization to bill the Medicare program and the respective Medicaid program in the
state or states in which such entity operates unless failure to maintain such provider number or other authorization could not
be expected, individually or in the aggregate, to result in a Material Adverse Change; neither the Company nor any of its subsidiaries
is subject to any pending or, to the Company’s knowledge, threatened or contemplated action which could reasonably be expected
to result either in a revocation of any provider number or authorization or in the Company’s or any subsidiary’s exclusion
from the Medicare or any state Medicaid programs; the Company’s and each of its subsidiaries’ business practices have
been structured in a manner reasonably designed to comply with the federal or state laws governing Medicare and state Medicaid
programs, including, without limitation, Sections 1320a-7a and 1320a-7b of Title 42 of the United States Code, and the Company
reasonably believes that it is in compliance with such laws; the Company and its subsidiaries have taken reasonable actions designed
to ensure that they do not: (i) violate the False Claims Act, 31 U.S.C. §§ 3729-3733 or (ii) allow any individual with
an ownership or control interest (as defined in 42 U.S.C. § 1320a-3(a)(3)) in the Company or any of its subsidiary or have
any officer, director or managing employee (as defined in 42 U.S.C. § 1320a-5(b)) of the Company or any of its subsidiaries
who would be a person excluded from participation in any federal health care program (as defined in 42 U.S.C. § 1320a-7b(f))
as described in 42 U.S.C. § 1320a-7(b)(8); and the Company and its subsidiaries have structured their respective businesses
practices in a manner reasonably designed to comply with the federal and state laws regarding physician ownership of (or financial
relationship with), and referral to, entities providing healthcare-related goods or services, and with laws requiring disclosure
of financial interests held by physicians in entities to which they may refer patients for the provisions of healthcare-related
goods or services, and the Company reasonably believes that it and its subsidiaries are in compliance with such laws.
(pp) Compliance
with Health Care Laws. The Company and its subsidiaries are, and at all times have been, in material compliance with all Health
Care Laws. For purposes of this Agreement, “Health Care Laws” means: (i) the Federal Food, Drug, and Cosmetic Act (21
U.S.C. Section 301 et seq.), the Public Health Service Act (42 U.S.C. Section 201 et seq.), and the regulations promulgated thereunder;
(ii) all applicable federal, state, local and foreign health care fraud and abuse laws, including, without limitation, the Anti-Kickback
Statute (42 U.S.C. Section 1320a-7b(b)), the Civil False Claims Act (31 U.S.C. Section 3729 et seq.), the criminal false statements
law (42 U.S.C. Section 1320a-7b(a)), 18 U.S.C. Sections 286 and 287, the health care fraud criminal provisions under the U.S. Health
Insurance Portability and Accountability Act of 1996 (“HIPAA”) (42 U.S.C. Section 1320d et seq.), the Stark Law (42
U.S.C. Section 1395nn), the civil monetary penalties law (42 U.S.C. Section 1320a-7a), the exclusion law (42 U.S.C. Section 1320a-7),
the Physician Payments Sunshine Act (42 U.S.C. Section 1320-7h), and applicable laws governing government funded or sponsored healthcare
programs; (iii) HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act (42 U.S.C. Section
17921 et seq.); (iv) the Patient Protection and Affordable Care Act of 2010, as amended by the Health Care and Education Reconciliation
Act of 2010; (v) licensure, quality, safety and
accreditation requirements
under applicable federal, state, local or foreign laws or regulatory bodies; (vi) the collection and reporting requirements, and
the processing of any applicable rebate, chargeback or adjustment, under applicable rules and regulations relating to the Medicaid
Drug Rebate Program (42 U.S.C. § 1396r-8) and any state supplemental rebate program, state drug price transparency law , Medicare
average sales price reporting (42 U.S.C. § 1395w-3a), the Public Health Service Act (42 U.S.C. § 256b), the federal TRICARE
program (10 U.S.C. §§ 1071 et seq.), the VA Federal Supply Schedule (38 U.S.C. § 8126) or under any state pharmaceutical
assistance program or U.S. Department of Veterans Affairs agreement, (vii) all other local, state, federal, national, supranational
and foreign laws, relating to the regulation of the Company or its subsidiaries, and (viii) the directives and regulations promulgated
pursuant to such statutes and any state or non-U.S. counterpart thereof. Neither the Company nor any of its subsidiaries has received
written notice of any claim, action, suit, proceeding, hearing, enforcement, investigation, arbitration or other action from any
court or arbitrator or governmental or regulatory authority or third party alleging that any product operation or activity is in
violation of any Health Care Laws nor, to the Company’s knowledge, is any such claim, action, suit, proceeding, hearing,
enforcement, investigation, arbitration or other action threatened. The Company and its subsidiaries have filed, maintained or
submitted all material reports, documents, forms, notices, applications, records, claims, submissions and supplements or amendments
as required by any Health Care Laws, and all such reports, documents, forms, notices, applications, records, claims, submissions
and supplements or amendments were complete and accurate on the date filed in all material respects (or were corrected or supplemented
by a subsequent submission). Neither the Company nor any of its subsidiaries is a party to any corporate integrity agreements,
monitoring agreements, consent decrees, settlement orders, or similar agreements with or imposed by any governmental or regulatory
authority. Additionally, neither the Company, any of its subsidiaries nor any of their respective employees, officers, directors,
or agents has been excluded, suspended or debarred from participation in any U.S. federal health care program or human clinical
research or, to the knowledge of the Company, is subject to a governmental inquiry, investigation, proceeding, or other similar
action that could reasonably be expected to result in debarment, suspension, or exclusion.
(qq) Validity
of Choice of Law. The choice of the law of the State of New York as the governing law of this Agreement is a valid choice of
law under the laws of Luxembourg and will be recognized by courts in Luxembourg, except that a Luxembourg court may refuse to apply
the law of the State of New York if, amongst others, such law is contrary to overriding mandatory provisions (lois de police)
of Luxembourg or such law would be manifestly incompatible with the public policy (ordre public) of Luxembourg. The Company
has the power to submit, and pursuant to Section 8(g) of this Agreement, has legally, validly, effectively and irrevocably
submitted, to the personal jurisdiction of each United States federal court and New York state court located in the Borough of
Manhattan, in the City of New York, New York, United States (each, a “New York Court”), and the Company has
the power to designate, appoint and authorize, and pursuant to Section 8(g) of this Agreement, has legally, validly, effectively
and irrevocably designated, appointed an authorized agent for service of process in any action arising out of or relating to this
Agreement or the Shares in any New York Court, and service of process effected on such authorized agent will be effective to confer
valid personal jurisdiction over the Company as provided in Section 8(g) of this Agreement.
(rr) No
Immunity. Neither the Company nor the Subsidiary nor any of their properties or assets has any immunity from the jurisdiction
of any court or from any legal process (whether through service or notice, attachment prior to judgment, attachment in aid of execution
or otherwise), including under the laws of Luxembourg.
(ss) Enforcement
of Judgments. Subject to the conditions and qualifications set forth in the Registration Statement and Prospectus, any final
judgment for a fixed sum of money rendered by a New York Court having jurisdiction under New York law in respect of any suit, action
or proceeding against the Company based upon this Agreement would be recognized and enforced against the Company by Luxembourg
courts, subject to the applicable enforcement (exequatur) procedure, without re-examining the merits of the case; provided
that (A) such judgment is enforceable (exécutoire) in New York; (B) the New York court awarding the judgment has
jurisdiction to adjudicate the matter under applicable New York rules and according to the Luxembourg conflict of jurisdictions
rules; (C) the New York court has acted in accordance with its own procedural rules and has applied to the dispute the substantive
law which would have been applied by Luxembourg courts (although some first instance decisions rendered in Luxembourg – which
have not been confirmed by the Court of Appeal – no longer apply this condition); (D) the principles of fair trial and due
process have been complied with and in particular such judgement was granted following proceedings where the counterparty had the
opportunity to appear, and if appeared, to present a defense; and (E) such judgement does not contravene Luxembourg public policy
(ordre public) and has not been obtained fraudulently.
(tt) Market
Abuse. The sale or issuance of the Shares will not violate the provisions of the EU Market Abuse Regulation.
Any certificate signed
by any officer or representative of the Company or any of its subsidiaries and delivered to the Agent or counsel for the Agent
in connection with an issuance of Shares shall be deemed a representation and warranty by the Company to the Agent as to the matters
covered thereby on the date of such certificate.
The Company acknowledges
that the Agent and, for purposes of the opinions to be delivered pursuant to Section 4(o) hereof, counsel to the Company
and counsel to the Agent, will rely upon the accuracy and truthfulness of the foregoing representations and hereby consents to
such reliance.
Section 3. ISSUANCE AND/OR SALE OF
SHARES
(a) Sale
of Securities. On the basis of the representations, warranties and agreements herein contained, but subject to the terms and
conditions herein set forth, the Company and the Agent agree that the Company may from time to time seek to sell and/or issue Shares
through the Agent, acting as sales agent, or directly to the Agent, acting as principal, as follows, with an aggregate Sales Price
of up to the Maximum Program Amount, based on and in accordance with Issuance Notices as the Company may deliver, during the Agency
Period.
(b) Mechanics
of Issuances.
(i) Issuance Notice.
Upon the terms and subject to the conditions set forth herein, on any Trading Day during the Agency Period on which the conditions
set forth in Section 5(a) and
Section
5(b) shall have been satisfied, the Company may exercise its right to request an issuance and/or delivery of Shares
by delivering to the Agent an Issuance Notice; provided, however, that (A) in no event may the Company deliver an Issuance
Notice to the extent that (I) the sum of (x) the aggregate Sales Price of the requested Issuance Amount, plus (y) the aggregate
Sales Price of all Shares issued under all previous Issuance Notices effected pursuant to this Agreement, would exceed the Maximum
Program Amount; and (B) prior to delivery of any Issuance Notice, the period set forth for any previous Issuance Notice shall have
expired or been terminated. An Issuance Notice shall be considered delivered on the Trading Day that it is received by e-mail to
the persons set forth in Schedule A hereto and confirmed by the Company by telephone (including a voicemail message to the persons
so identified), with the understanding that, with adequate prior written notice, the Agent may modify the list of such persons
from time to time. The Company will specify in the Issuance Notice whether the Shares shall be New Shares or Treasury Shares.
(ii) Agent Efforts.
Upon the terms and subject to the conditions set forth in this Agreement, upon the receipt of an Issuance Notice, the Agent will
use its commercially reasonable efforts consistent with its normal sales and trading practices to place the Shares with respect
to which the Agent has agreed to act as sales agent, subject to, and in accordance with the information specified in, the Issuance
Notice, unless the sale of the Shares described therein has been suspended, cancelled or otherwise terminated in accordance with
the terms of this Agreement. For the avoidance of doubt, the parties to this Agreement may modify an Issuance Notice at any time
provided they both agree in writing to any such modification.
(iii) Method of
Offer and Sale. The Shares may be offered and sold (A) in negotiated transactions with the consent of the Company or (B) by
any other method permitted by law deemed to be an “at the market offering” as defined in Rule 415(a)(4) under the Securities
Act, including block transactions, sales made directly on the Principal Market or sales made into any other existing U.S. trading
market of the Ordinary Shares. Nothing in this Agreement shall be deemed to require either party to agree to the method of offer
and sale specified in the preceding sentence, and (except as specified in clause (A) above) the method of placement of any Shares
by the Agent shall be at the Agent’s discretion, except that the Agent shall be bound by the election of the Company between
Treasury Shares and New Shares and the relevant procedures applying.
(iv) Confirmation
to the Company. If acting as sales agent hereunder, the Agent will provide no later than 10:00 p.m. ET on the Placement Date
written confirmation to the Company setting forth the number of Shares placed on such Trading Day, the corresponding Sales Price,
as well as the Nominal Price (in case of New Shares) and the Settlement Price (in case of New Shares) payable to the Company in
respect thereof and the Selling Commission payable to the Agent in respect thereof. In case of New Shares, the Agent will (i) provide
the subscription certificate in the form provided in Exhibit B together with such written confirmation, (ii) ensure that the Nominal
Price is wired to the Bank Account on the Placement Date and received in the Bank Account prior to the issuance of the New Shares
by the Company on the Settlement Date and (iii) irrevocably undertake to contribute the Settlement Price to the equity of the Company
without issuing new shares (account 115 of the standard chart of accounts “apport en capitaux propres non rémunérés
par des titres”) and ensure that the Settlement Price is received in the Bank Account on the Settlement Date following
the issuance of the New Shares by the Company and prior to the delivery by the Agent of the placed New Shares to any third party.
The Agent acknowledges and agrees that the Company will not be in a position to deliver New Shares in case of delay of payment
of the Nominal Price.
In case of Treasury Shares, the Agent will ensure that the Sales Price is received in the Bank Account on the Trading Day immediately
following the Placement Date and the Company shall subsequently remit the Selling Commission to the Agent in immediately available
funds to an account designated in writing by the Agent, no later than the Trading Day following the Placement Date.
(v) Settlement.
Each issuance or sale of Shares will be settled on the applicable Settlement Date for such issuance or sale of Shares subject to
the action referred to under Section 3(b)(iv) having been taken in due time, subject to the provisions of Section 5, and,
in case of New Shares, subject to the Nominal Price having been received in the Bank Account. On or before each Settlement Date,
the Company will, or will cause its transfer agent to, electronically transfer the Shares being sold by crediting the Agent or
its designee’s account at The Depository Trust Company through its Deposit/Withdrawal At Custodian (DWAC) System, or by such
other means of delivery as may be mutually agreed upon by the parties hereto and, upon receipt of such Shares, which in all cases
shall be freely tradable, transferable, registered shares in good deliverable form, the Agent will deliver, by wire transfer of
immediately available funds, the related Settlement Price in case of New Shares and the Sale Price in case of Treasury Shares in
same day funds delivered to an account designated by the Company prior to the Settlement Date. In case of the sales of New Shares,
the board of directors of the Company shall (i) take the resolutions to issue such shares from its authorized capital, to be acknowledged
in front of a Luxembourg notary within one month of such resolution and provide the Agent with evidence of such action and (ii)
take resolutions to accept the contribution of the Settlement Price to the equity of the Company without issuing new shares (account
115 of the standard chart of accounts “apport en capitaux propres non rémunérés par des titres”).
The Company may sell Shares to the Agent as principal at a price agreed upon at each relevant time Shares are sold pursuant to
this Agreement (each, a “Time of Sale”).
(vi) Suspension
or Termination of Sales. Consistent with standard market settlement practices, the Company or the Agent may, upon notice
to the other party hereto in writing or by telephone (confirmed immediately by verifiable email), suspend any sale of Shares,
and the period set forth in an Issuance Notice shall immediately terminate; provided, however, that (A) such
suspension and termination shall not affect or impair either party’s obligations with respect to any Shares placed or
sold hereunder prior to the receipt of such notice; (B) if the Company suspends or terminates any sale of Shares after the
Agent confirms such sale to the Company, the Company shall still be obligated to comply with Section 3(b)(v) with
respect to such Shares; and (C) if the Company defaults in its obligation to deliver Shares on a Settlement Date (except in
case the Agent fails to comply with Section 3(b)(iv)), the Company agrees that it will hold the Agent harmless against
any loss, claim, damage or expense (including, without limitation, penalties, interest and reasonable and documented legal
fees and expenses), as incurred, arising out of or in connection with such default by the Company. The parties hereto
acknowledge and agree that, in performing its obligations under this Agreement, the Agent may borrow Ordinary Shares from
stock lenders in the event that the Company has not delivered Shares (except in case the Agent fails to comply with Section
3(b)(iv)) to settle sales as required by subsection (v) above, and may use the Shares to settle or close out such
borrowings. The Company agrees that no such notice shall be effective against the Agent unless it is made to the persons
identified in writing by the Agent pursuant to Section 3(b)(i).
(vii) No
Guarantee of Placement, Etc. The Company acknowledges and agrees that (A) there can be no assurance that the Agent will
be successful in placing Shares; (B) the Agent will incur no liability or obligation to the Company or any other Person if it
does not sell Shares; and (C) the Agent shall be under no obligation to purchase Shares on a principal basis pursuant to this
Agreement, except as otherwise specifically agreed by the Agent and the Company.
(viii) Selling
Restrictions. The Shares described in this Agreement are not intended to be offered, sold, distributed or otherwise made available
to and should not be offered, sold, distributed or otherwise made available to any retail investor in the European Economic Area
(“EEA”). For these purposes, a retail investor means a person who is one (or more) of: (i) a retail client as defined
in point (11) of Article 4(1) of Directive 2014/65/EU (“MiFID II”); or (ii) a customer within the meaning of Directive
(EU) 2016/97, where that customer would not qualify as a professional client as defined in point (10) of Article 4(1) of MiFID
II; or (iii) not a qualified investor as defined in the EU Prospectus Regulation. Consequently, no key information document required
by Regulation (EU) No 1286/2014 (as amended, the “PRIIPs Regulation”) for offering, selling or distributing the Shares
described in this Agreement or otherwise making them available to retail investors in the EEA has been prepared and therefore offering,
selling or distributing such Shares or otherwise making them available to any retail investor in the EEA may be unlawful under
the PRIIPs Regulation. Any offer of such Shares in any member state of the EEA will be made pursuant to an exemption under the
EU Prospectus Regulation from the requirement to publish a prospectus for offers of such Shares.
(ix) Material
Non-Public Information. Notwithstanding any other provision of this Agreement, the Company and the Agent
agree that the Company shall not deliver any Issuance Notice to the Agent, and the Agent shall not be obligated to place any
Shares, during any period in which the Company is in possession of material non-public information or any inside information
(as such term is defined in the EU Market Abuse Regulation).
(x) Fees. As
compensation for services rendered, the Company shall pay to the Agent, on the applicable Settlement Date, the Selling Commission
for the applicable Issuance Amount (including with respect to any suspended or terminated sale pursuant to Section 3(b)(vi))
by the Agent deducting the Selling Commission from the applicable Issuance Amount.
(xi) Expenses.
The Company agrees to pay all costs, fees and expenses incurred in connection with the performance of its obligations hereunder
and in connection with the transactions contemplated hereby, including without limitation (i) all expenses incident to the issuance
and delivery of the Shares (including all printing and engraving costs); (ii) all fees and expenses of the registrar and transfer
agent of the Shares; (iii) all necessary issue, transfer and other stamp taxes in connection with the issuance and sale of the
Shares; (iv) all fees and expenses of the Company’s counsel, civil law notary, independent public or certified public accountants
and other advisors; (v) all costs and expenses incurred in connection with the preparation, printing, filing, shipping and distribution
of the Registration Statement (including financial statements, exhibits, schedules, consents and certificates of experts), the
Prospectus, any Free Writing Prospectus (defined below) prepared by or on behalf of, used by, or referred to by the Company, and
all amendments and supplements thereto, and this Agreement; (vi) all filing fees, attorneys’ fees and expenses incurred by
the Company or the Agent in connection with qualifying or registering (or obtaining exemptions from the qualification or registration
of) all or any part of the Shares for offer and sale under the
state securities or blue
sky laws, and, if requested by the Agent, preparing and printing a “Blue Sky Survey”, and any supplements thereto,
advising the Agent of such qualifications, registrations, determinations and exemptions; (vii) the reasonable fees and disbursements
of the Agent’s counsel, including the reasonable fees and expenses of counsel for the Agent in connection with, FINRA review,
if any, and approval of the Agent’s participation in the offering and distribution of the Shares; (viii) the filing fees
incident to FINRA review, if any; and (ix) the fees and expenses associated with listing the Shares on the Principal Market. The
fees and disbursements of Agent’s counsel pursuant to subsections (vi) and (vii) above shall not exceed $100,000 for the
Agent’s U.S. counsel and $50,000 for Agent’s Luxembourg counsel in connection with the first Issuance Notice and (B)
$15,000 in the aggregate in connection with each Triggering Event Date (defined below) on which the Company is required to provide
a certificate pursuant to Section 4(o).
Section 4. ADDITIONAL COVENANTS
The Company covenants
and agrees with the Agent as follows, in addition to any other covenants and agreements made elsewhere in this Agreement:
(a) Exchange
Act Compliance. During the Agency Period, the Company shall (i) file, on a timely basis, with the Commission all reports and
documents required to be filed under Section 13, 14 or 15 of the Exchange Act in the manner
and within the time periods required by the Exchange Act; and (ii) either (A) include in its half-year
reports on Form 6-K (or Form 10-Q if applicable) and its annual reports on Form 20-F (or Form 10-K if applicable), a summary detailing,
for the relevant reporting period, (1) the number of Shares sold through the Agent pursuant to this Agreement and (2) the net proceeds
received by the Company from such sales or, in the Company’s sole discretion, or (B) prepare a prospectus supplement containing,
or include in such other filing permitted by the Securities Act or Exchange Act (each an “Interim Prospectus Supplement”),
such summary information and, at least once every six months and subject to this Section 4, file such Interim Prospectus Supplement
pursuant to Rule 424(b) under the Securities Act (and within the time periods required by Rule 424(b) and Rule 430B under the Securities
Act).
(b) Securities
Act Compliance. After the date of this Agreement, the Company shall promptly advise the Agent in writing (i) of the receipt
of any comments of, or requests for additional or supplemental information from, the Commission; (ii) of the time and date of any
filing of any post-effective amendment to the Registration Statement, any Rule 462(b) Registration Statement or any amendment or
supplement to the Prospectus, or any Free Writing Prospectus; (iii) of the time and date that any post-effective amendment to the
Registration Statement or any Rule 462(b) Registration Statement becomes effective; and (iv) of the issuance by the Commission
of any stop order suspending the effectiveness of the Registration Statement or any post-effective amendment thereto, any Rule
462(b) Registration Statement or any amendment or supplement to the Prospectus or of any order preventing or suspending the use
of any Free Writing Prospectus or the Prospectus, or of any proceedings to remove, suspend or terminate from listing or quotation
the Ordinary Shares from any securities exchange upon which they are listed for trading or included or designated for quotation,
or of the threatening or initiation of any proceedings for any of such purposes. If the Commission shall enter any such stop order
at any time, the Company will use its best efforts to obtain the lifting of such order as soon as practicable. Additionally, the
Company agrees that it shall comply with the provisions of Rule 424(b) and Rule 433, as
applicable, under the
Securities Act and will use its reasonable efforts to confirm that any filings made by the Company under such Rule 424(b) or Rule
433 were received in a timely manner by the Commission.
(c) Amendments
and Supplements to the Prospectus and Other Securities Act Matters. If any event shall occur or condition exist as a result
of which it is necessary to amend or supplement the Prospectus so that the Prospectus does not include an untrue statement of a
material fact or omit to state a material fact necessary in order to make the statements therein, in the light of the circumstances
when the Prospectus is delivered to a purchaser, not misleading, or if in the opinion of the Agent or counsel for the Agent it
is otherwise necessary to amend or supplement the Prospectus to comply with applicable law, including the Securities Act, the Company
agrees (subject to Sections 4(d) and 4(f)) to promptly prepare, file with the Commission and furnish at its own expense
to the Agent, amendments or supplements to the Prospectus so that the statements in the Prospectus as so amended or supplemented
will not include an untrue statement of a material fact or omit to state a material fact necessary in order to make the statements
therein, in the light of the circumstances when the Prospectus is delivered to a purchaser, not be misleading or so that the Prospectus,
as amended or supplemented, will comply with applicable law including the Securities Act. Neither the Agent’s consent to,
or delivery of, any such amendment or supplement shall constitute a waiver of any of the Company’s obligations under Sections
4(d) and 4(f). Notwithstanding the foregoing, the Company shall not be required to file such amendment or supplement if there is
no pending Issuance Notice and the Company believes that it is in its best interests not to file such amendment or supplement.
(d) Agent’s
Review of Proposed Amendments and Supplements. Prior to amending or supplementing the Registration Statement (including any
registration statement filed under Rule 462(b) under the Securities Act) or the Prospectus (excluding any amendment or supplement
through incorporation of any report filed under the Exchange Act), the Company shall furnish to the Agent for review, a reasonable
amount of time prior to the proposed time of filing or use thereof, a copy of each such proposed amendment or supplement, and the
Company shall not file or use any such proposed amendment or supplement without the Agent’s prior consent, and to file with
the Commission within the applicable period specified in Rule 424(b) under the Securities Act any prospectus required to be filed
pursuant to such Rule.
(e)
Use of Free Writing Prospectus. Neither the Company nor the Agent has prepared, used, referred to or distributed,
or will prepare, use, refer to or distribute, without the other party’s prior written consent, any “written communication”
that constitutes a “free writing prospectus” as such terms are defined in Rule 405 under the Securities Act with respect
to the offering contemplated by this Agreement (any such free writing prospectus being referred to herein as a “Free
Writing Prospectus”).
(f) Free
Writing Prospectuses. The Company shall furnish to the Agent for review, a reasonable amount of time prior to the proposed
time of filing or use thereof, a copy of each proposed free writing prospectus or any amendment or supplement thereto to be prepared
by or on behalf of, used by, or referred to by the Company and the Company shall not file, use or refer to any proposed free writing
prospectus or any amendment or supplement thereto without the Agent’s consent, which shall not be unreasonably withheld,
conditioned or delayed. The Company shall furnish to the Agent, without charge, as many copies of any free writing prospectus prepared
by
or on behalf of, or used
by the Company, as the Agent may reasonably request. If at any time when a prospectus is required by the Securities Act (including,
without limitation, pursuant to Rule 173(d)) to be delivered in connection with sales of the Shares (but in any event if at any
time through and including the date of this Agreement) there occurred or occurs an event or development as a result of which any
free writing prospectus prepared by or on behalf of, used by, or referred to by the Company conflicted or would conflict with the
information contained in the Registration Statement or included or would include an untrue statement of a material fact or omitted
or would omit to state a material fact necessary in order to make the statements therein, in the light of the circumstances prevailing
at that subsequent time, not misleading, the Company shall promptly amend or supplement such free writing prospectus to eliminate
or correct such conflict or so that the statements in such free writing prospectus as so amended or supplemented will not include
an untrue statement of a material fact or omit to state a material fact necessary in order to make the statements therein, in the
light of the circumstances prevailing at such subsequent time, not misleading, as the case may be; provided, however, that
prior to amending or supplementing any such free writing prospectus, the Company shall furnish to the Agent for review, a reasonable
amount of time prior to the proposed time of filing or use thereof, a copy of such proposed amended or supplemented free writing
prospectus and the Company shall not file, use or refer to any such amended or supplemented free writing prospectus without the
Agent’s consent, which shall not be unreasonably withheld, conditioned or delayed.
(g) Filing
of Agent Free Writing Prospectuses. The Company shall not take any action that would result in the Agent or the Company being
required to file with the Commission pursuant to Rule 433(d) under the Securities Act a free writing prospectus prepared by or
on behalf of the Agent that the Agent otherwise would not have been required to file thereunder.
(h) Copies
of Registration Statement and Prospectus. After the date of this Agreement through the last time that a prospectus is required
by the Securities Act (including, without limitation, pursuant to Rule 173(d)) to be delivered in connection with sales of the
Shares, the Company agrees to furnish the Agent with copies (which may be electronic copies) of the Registration Statement and
each amendment thereto, and with copies of the Prospectus and each amendment or supplement thereto in the form in which it is filed
with the Commission pursuant to the Securities Act or Rule 424(b) under the Securities Act, both in such quantities as the Agent
may reasonably request from time to time; and, if the delivery of a prospectus is required under the Securities Act or under the
blue sky or securities laws of any jurisdiction at any time on or prior to the applicable Settlement Date for any period set forth
in an Issuance Notice in connection with the offering or sale of the Shares and if at such time any event has occurred as a result
of which the Prospectus as then amended or supplemented would include an untrue statement of a material fact or omit to state any
material fact necessary in order to make the statements therein, in the light of the circumstances under which they were made when
such Prospectus is delivered, not misleading, or, if for any other reason it is necessary during such same period to amend or supplement
the Prospectus or to file under the Exchange Act any document incorporated by reference in the Prospectus in order to comply with
the Securities Act or the Exchange Act, to notify the Agent and to request that the Agent suspend offers to sell Shares (and, if
so notified, the Agent shall cease such offers as soon as practicable); and if the Company decides to amend or supplement the Registration
Statement or the Prospectus as then amended or supplemented, to advise the Agent promptly by telephone (with confirmation in writing)
and to prepare and cause to be filed promptly with the Commission an amendment or supplement to the Registration
Statement or the Prospectus
as then amended or supplemented that will correct such statement or omission or effect such compliance; provided, however,
that if during such same period the Agent is required to deliver a prospectus in respect of transactions in the Shares, the Company
shall promptly prepare and file with the Commission such an amendment or supplement.
(i) Blue
Sky Compliance. The Company shall cooperate with the Agent and counsel for the Agent to qualify or register the Shares for
sale under (or obtain exemptions from the application of) the state securities or blue sky laws or laws of such jurisdiction designated
by the Agent, shall comply with such laws and shall continue such qualifications, registrations and exemptions in effect so long
as required for the distribution of the Shares. The Company shall not be required to qualify as a foreign corporation or to take
any action that would subject it to general service of process in any such jurisdiction where it is not presently qualified or
where it would be subject to taxation as a foreign corporation. The Company will advise the Agent promptly of the suspension of
the qualification or registration of (or any such exemption relating to) the Shares for offering, sale or trading in any jurisdiction
or any initiation or threat of any proceeding for any such purpose, and in the event of the issuance of any order suspending such
qualification, registration or exemption, the Company shall use its best efforts to obtain the withdrawal thereof as soon as practicable.
(j) Earnings
Statement. As soon as practicable, the Company will make generally available to its security holders and to the Agent an earnings
statement (which need not be audited) covering a period of at least twelve months beginning with the first fiscal quarter of the
Company occurring after the date of this Agreement which shall satisfy the provisions of Section 11(a) of the Securities Act and
Rule 158 under the Securities Act, which requirement may be satisfied by publicly filing the required information on EDGAR.
(k) Listing;
Reservation of Shares. (a) The Company will use its best efforts to maintain the listing of the Shares on the Principal Market;
and (b) the Company will reserve and keep available at all times, free of preemptive rights, Shares for the purpose of enabling
the Company to satisfy its obligations under this Agreement.
(l) Transfer
Agent. The Company shall engage and maintain, at its expense, a registrar and transfer agent for the Shares.
(m) Due
Diligence. During the term of this Agreement, the Company will reasonably cooperate with any reasonable due diligence review
conducted by the Agent in connection with the transactions contemplated hereby, including, without limitation, providing information
and making available documents and senior corporate officers, during normal business hours and at the Company’s principal
offices, as the Agent may reasonably request from time to time.
(n) Representations
and Warranties. The Company acknowledges that each delivery of an Issuance Notice and each delivery of Shares on a Settlement
Date shall be deemed to be (i) an affirmation to the Agent that the representations and warranties of the Company contained in
or made pursuant to this Agreement are true and correct as of the date of such Issuance Notice or of such Settlement Date, as the
case may be, as though made at and as of each such date, except as may be disclosed in the Prospectus (including any documents
incorporated by reference therein and any supplements thereto); and (ii) an undertaking that the Company will advise the Agent
if
any of such representations
and warranties will not be true and correct as of the Settlement Date for the Shares relating to such Issuance Notice, as though
made at and as of each such date (except that such representations and warranties shall be deemed to relate to the Registration
Statement and the Prospectus as amended and supplemented relating to such Shares).
(o)
Deliverables at Triggering Event Dates; Certificates. The Company agrees that on or prior to the date of the first
Issuance Notice and, during the term of this Agreement after the date of the first Issuance Notice, upon:
(A) the filing of the
Prospectus or the amendment or supplement of any Registration Statement or Prospectus (other than a prospectus supplement relating
solely to an offering of securities other than the Shares or a prospectus filed pursuant to Section 4(a)(ii)(B)), by means of a
post-effective amendment, sticker or supplement, but not by means of incorporation of documents by reference into the Registration
Statement or Prospectus; or
(B) the filing with
the Commission of an annual report on Form 20-F (or Form 10-K, if applicable) or half-year financial statements on Form 6-K (or
Form 10-Q, if applicable) under the Exchange Act, (including any Form 20-F/A or Form 6-K/A containing amended financial information
or a material amendment to the previously filed report on Form 6-K or Form 20-F), in each case, of the Company;
(any such event, a “Triggering
Event Date”), the Company shall furnish the Agent with a certificate as of the Triggering Event Date, in the form and
substance satisfactory to the Agent and its counsel, substantially similar to the form previously provided to the Agent and its
counsel, modified, as necessary, to relate to the Registration Statement and the Prospectus as amended or supplemented, (A) confirming
that the representations and warranties of the Company contained in this Agreement are true and correct, (B) confirming that the
Company has performed all of its obligations hereunder to be performed on or prior to the date of such certificate and as to the
matters set forth in Section 5(a)(iii) hereof, and (C) containing any other certification that the Agent shall reasonably
request. The requirement to provide a certificate under this Section 4(o) shall be waived for any Triggering Event Date
occurring at a time when no Issuance Notice is pending or a suspension is in effect, which waiver shall continue until the earlier
to occur of the date the Company delivers instructions for the sale of Shares hereunder (which for such half-year period shall
be considered a Triggering Event Date) and the next occurring Triggering Event Date. Notwithstanding the foregoing, if the Company
subsequently decides to sell Shares following a Triggering Event Date when a suspension was in effect and did not provide the Agent
with a certificate under this Section 4(o), then before the Company delivers the instructions for the sale of Shares or the Agent
sells any Shares pursuant to such instructions, the Company shall provide the Agent with a certificate in conformity with this
Section 4(o) dated as of the date that the instructions for the sale of Shares are issued.
(p) Legal
Opinions. On or prior to the date of the first Issuance Notice and on or prior to each Triggering Event Date with respect
to which the Company is obligated to deliver a certificate pursuant to Section 4(o) for which no waiver is applicable
and excluding the date of this Agreement, a negative assurance letter and the written legal opinion of Cooley LLP, U.S.
counsel to the Company, and a written legal opinion of Arendt & Medernach SA, Luxembourg counsel to the Company,
each dated the date of delivery, in form and substance reasonably satisfactory to the
Agent
and its counsel, substantially similar to the form previously provided to the Agent and its counsel, modified, as necessary, to
relate to the Registration Statement and the Prospectus as then amended or supplemented. In lieu of such opinions for subsequent
periodic filings, in the discretion of the Agent, the Company may furnish a reliance letter from such counsel to the Agent, permitting
the Agent to rely on a previously delivered opinion letter, modified as appropriate for any passage of time or Triggering Event
Date (except that statements in such prior opinion shall be deemed to relate to the Registration Statement and the Prospectus
as amended or supplemented as of such Triggering Event Date). The Company shall be required to furnish no more than one set of
legal opinions hereunder per each filing of an annual report on Form 20-F (or Form 10-K, if applicable) or a report on Form 6-K
containing half-year financial information (or Form 10-Q, if applicable).
(q) Comfort
Letter. On or prior to the date of the first Issuance Notice and on or prior to each Triggering Event Date with respect to
which the Company is obligated to deliver a certificate pursuant to Section 4(o) for which no waiver is applicable and excluding
the date of this Agreement, the Company shall cause Deloitte ehf, the independent registered public accounting firm who has audited
the annual financial statements included or incorporated by reference in the Registration Statement, to furnish the Agent a comfort
letter, dated the date of delivery, in form and substance reasonably satisfactory to the Agent and its counsel, substantially similar
to the form previously provided to the Agent and its counsel; provided, however, that any such comfort letter will only
be required on the Triggering Event Date specified to the extent that it contains annual or half-year financial statements filed
with the Commission under the Exchange Act and incorporated or deemed to be incorporated by reference into the Prospectus. The
occurrence of any material transaction or event requiring the filing of a report on Form 6-K (or Form 8-K) containing material
amended financial information of the Company, including the restatement of the Company’s financial statements, shall be deemed
a Triggering Event Date, and, only if requested by the Agent upon Agent’s reasonable determination that the information contained
in such report is material, the Company shall also cause a comfort letter to be furnished to the Agent prior to any additional
sales of Shares.
(r) Director’s
Certificate. On or prior to the date of the first Issuance Notice and on each Triggering
Event Date, the Company shall furnish the Agent a certificate executed by a director of the Company, signing in such capacity,
dated the date of delivery (the “Certificate Date”) (i) certifying that attached thereto are true and complete
copies of the resolutions duly adopted by the Board of Directors of the Company authorizing the execution and delivery of this
Agreement and the consummation of the transactions contemplated hereby (including, without limitation, the issuance or sale of
the Shares pursuant to this Agreement), which authorization shall be in full force and effect on and as of the Certificate Date,
(ii) certifying that attached thereto is a true and complete copy of the restated articles of association (statuts coordonnés)
of the Company, (iii) certifying that attached thereto are true and complete (x) electronic excerpt (extrait) issued by
the Luxembourg Register of Commerce and Companies dated the Certificate Date and (y) electronic certificate of non-registration
of judicial decision or administrative dissolution without liquidation (certificat de non-inscription d’une décision
judiciaire ou de dissolution administrative sans liquidation) issued by the Luxembourg Insolvency Register (Reginsol, Registre
de l’Insolvabilité) held by the Luxembourg Register of Commerce and Companies dated the Certificate Date, (iv)
certifying and attesting to the office, incumbency, due authority and specimen signatures of each Person who executed this Agreement
for or on behalf of the Company, (v) certifying that each copy document relating to the Company specified in this paragraph (r)
is
correct,
complete and in full force and effect and as the Certificate Date, (vi) certifying that the Company is not subject to nor, as applicable,
does it meet or threaten to meet the criteria of bankruptcy (faillite), administrative dissolution without liquidation proceedings
(procédure de dissolution administrative sans liquidation), insolvency, voluntary or judicial liquidation (liquidation
volontaire ou judiciaire), out-of-court mutual agreement (réorganisation extra-judiciaire par accord amiable),
judicial reorganisation in the form of a stay to enter into a mutual agreement (sursis en vue de la conclusion d’un accord
amiable), judicial reorganisation by collective agreement (réorganisation judiciaire par accord collectif), judicial
reorganisation by transfer of assets or activities (réorganisation judiciaire par transfert sous autorité de justice),
conciliation (conciliation) or protective measures (mesures en vue de préserver les entreprises), reprieve
from payment (sursis de paiement), general settlement with creditors, reorganization or similar laws affecting the rights
of creditors generally and no application has been made or is to be made by its directors or, as far as it is aware, by any other
person for the appointment of a mandataire judiciaire, conciliateur, juge-commissaire, liquidateur, curateur or similar
officer pursuant to any voluntary or judicial insolvency, winding-up, liquidation or similar proceedings, (vii) certifying that
the Company complies with all requirements of the Luxembourg legislation and regulations on the domiciliation of companies, and
in particular with the Luxembourg Act dated 31 May 1999 on the domiciliation of companies, as amended from time to time, and (viii)
containing any other certification that the Agent shall reasonably request.
(s) Agent’s
Own Account; Clients’ Account. The Company consents to the Agent trading, in compliance with applicable law, in the Ordinary
Shares for the Agent’s own account and for the account of its clients at the same time as sales of the Shares occur pursuant
to this Agreement.
(t) Investment
Limitation. The Company shall not invest, or otherwise use the proceeds received by the Company from its sale of the Shares
in such a manner as would require the Company or any of its subsidiaries to register as an investment company under the Investment
Company Act.
(u) Market
Activities. The Company will not take, directly or indirectly, any action designed to or that might be reasonably expected
to cause or result in stabilization or manipulation of the price of the Shares or any other reference security, whether to facilitate
the sale or resale of the Shares or otherwise, and the Company will, and shall cause each of its Affiliates to, comply with all
applicable provisions of Regulation M. If the limitations of Rule 102 of Regulation M (“Rule 102”) do not apply
with respect to the Shares or any other reference security pursuant to any exception set forth in Section (d) of Rule 102, then
promptly upon notice from the Agent (or, if later, at the time stated in the notice), the Company will, and shall cause each of
its Affiliates to, comply with Rule 102 as though such exception were not available but the other provisions of Rule 102 (as interpreted
by the Commission) did apply. The Company shall promptly notify the Agent if it no longer meets the requirements set forth in Section
(d) of Rule 102.
(v) Notice
of Other Sale. Without the written consent of the Agent, the Company will not, directly or indirectly, offer to sell, sell,
contract to sell, grant any option to sell or otherwise dispose of any Ordinary Shares or securities convertible into or exchangeable
for Ordinary Shares (other than Shares hereunder), warrants or any rights to purchase or acquire Ordinary Shares, during the period
beginning on the Trading Day immediately prior to the date on which any
Issuance Notice is delivered
to the Agent hereunder and ending on the Trading Day immediately following the Settlement Date with respect to Shares sold pursuant
to such Issuance Notice; and will not directly or indirectly enter into any other “at the market” or continuous equity
transaction offer to sell, sell, contract to sell, grant any option to sell or otherwise dispose of any Ordinary Shares (other
than the Shares offered pursuant to this Agreement) or securities convertible into or exchangeable for Ordinary Shares, warrants
or any rights to purchase or acquire, Ordinary Shares prior to the termination of this Agreement; provided, however, that
such restrictions will not be required in connection with the Company’s (i) issuance or sale of Ordinary Shares, options
to purchase Ordinary Shares or Ordinary Shares issuable upon the exercise of options or other equity awards pursuant to any employee
or director share option, incentive or benefit plan, share purchase or ownership plan, long-term incentive plan, dividend reinvestment
plan, inducement award under Nasdaq rules or other compensation plan of the Company or its subsidiaries, as in effect on the date
of this Agreement, (ii) issuance or sale of Ordinary Shares issuable upon exchange, conversion or redemption of securities or the
exercise or vesting of warrants, options or other equity awards outstanding at the date of this Agreement, (iii) modification of
any outstanding options, warrants of any rights to purchase or acquire Ordinary Shares and (iv) issuance or sale of Ordinary Shares
or securities convertible into or exchangeable for Ordinary Shares in connection with mergers, acquisitions, other business combination,
strategic transactions including joint ventures, manufacturing, marketing, sponsored research, collaboration, license or distribution
arrangements which are not issued primarily for capital raising purposes, provided that the aggregate number of Ordinary Shares
or securities convertible into or exchangeable for Ordinary Shares issued or sold under this subsection (iv) shall not exceed 5%
of the number of Ordinary Shares outstanding immediately prior to giving effect to such sale of issuance.
Section 5. CONDITIONS TO DELIVERY
OF ISSUANCE NOTICES AND TO SETTLEMENT
(a) Conditions
Precedent to the Right of the Company to Deliver an Issuance Notice and the Obligation of the Agent to Sell Shares. The right
of the Company to deliver an Issuance Notice hereunder is subject to the satisfaction, on the date of delivery of such Issuance
Notice, and the obligation of the Agent to use its commercially reasonable efforts to place Shares during the applicable period
set forth in the Issuance Notice is subject to the satisfaction, on each Trading Day during the applicable period set forth in
the Issuance Notice, of each of the following conditions:
| (i) | Accuracy of the Company’s Representations and Warranties; Performance by the Company.
The Company shall have delivered the certificate required to be delivered pursuant to Section 4(o) on or before the date
on which delivery of such certificate is required pursuant to Section 4(o). The Company shall have performed, satisfied
and complied with all covenants, agreements and conditions required by this Agreement to be performed, satisfied or complied with
by the Company at or prior to such date, including, but not limited to, the covenants contained in Section 4(m), Section
4(q) and Section 4(r). |
| (ii) | No Injunction. No statute, rule, regulation, executive order, decree, ruling or injunction
shall have been enacted, entered, promulgated or endorsed by any court or governmental authority of competent jurisdiction or any
self-regulatory |
organization
having authority over the matters contemplated hereby that prohibits or directly and materially adversely affects any of the transactions
contemplated by this Agreement, and no proceeding shall have been commenced that may have the effect of prohibiting or materially
adversely affecting any of the transactions contemplated by this Agreement.
| (iii) | Material Adverse Changes. Except as disclosed in the Prospectus and the Time of Sale Information,
(a) in the judgment of the Agent there shall not have occurred any Material Adverse Change; and (b) there shall not have occurred
any downgrading, nor shall any notice have been given of any intended or potential downgrading or of any review for a possible
change that does not indicate the direction of the possible change, in the rating accorded any securities of the Company or any
of its subsidiaries by any “nationally recognized statistical rating organization” as such term is defined for purposes
of Section 3(a)(62) of the Exchange Act. |
| (iv) | No Suspension of Trading in or Delisting of Ordinary Shares; Other Events. The trading of
the Ordinary Shares (including without limitation the Shares) shall not have been suspended by the Commission, the Principal Market
or FINRA and the Ordinary Shares (including without limitation the Shares) shall have been approved for listing or quotation on
and shall not have been delisted from the Principal Market. There shall not have occurred (and be continuing in the case of occurrences
under clauses (i) and (ii) below) any of the following: (i) trading or quotation in any of the Company’s securities shall
have been suspended or limited by the Commission, the Principal Market or trading in securities generally on the Principal Market
or shall have been suspended or limited, or minimum or maximum prices shall have been generally established on any of such stock
exchanges by the Commission or FINRA; (ii) a general banking moratorium shall have been declared by any of federal or New York
authorities or Luxembourg or European authorities; or (iii) there shall have occurred any outbreak or escalation of national or
international hostilities or any crisis or calamity, or any change in the United States or international financial markets, or
any substantial change or development involving a prospective substantial change in United States’ or international political,
financial or economic conditions, as in the judgment of the Agent is material and adverse and makes it impracticable to market
the Shares in the manner and on the terms described in the Prospectus or to enforce contracts for the sale of securities. |
(b)
Documents Required to be Delivered on each Issuance Notice Date. The Agent’s obligation to use its commercially
reasonable efforts to place Shares hereunder shall additionally be conditioned upon the delivery to the Agent on or before the
Issuance Notice Date of a certificate in form and substance reasonably satisfactory to the Agent, executed by the Chief Executive
Officer, President or Chief Financial Officer or director and duly authorized signatory of the Company, to the effect that all
conditions to the delivery of such Issuance Notice shall have been satisfied as at the date of such certificate (which certificate
shall not be required if the foregoing representations shall be set forth in the Issuance Notice).
(c) No
Misstatement or Material Omission. The Agent shall not have advised the Company that the Registration Statement, the Prospectus
or the Time of Sales Information, or any amendment or supplement thereto, contains an untrue statement of fact that in the Agent’s
reasonable opinion is material, or omits to state a fact that in the Agent’s reasonable opinion is material and is required
to be stated therein or is necessary to make the statements therein not misleading.
(d) Agent
Counsel Legal Opinion. Agent shall have received from Paul Hastings LLP, counsel for Agent, such opinion or opinions, on or
before the date on which the delivery of the Company counsel legal opinion is required pursuant to Section 4(o), with respect
to such matters as Agent may reasonably require, and the Company shall have furnished to such counsel such documents as they request
for enabling them to pass upon such matters.
Section 6. INDEMNIFICATION AND CONTRIBUTION
(a) Indemnification
of the Agent. The Company agrees to indemnify and hold harmless the Agent, its officers and employees, and each person, if
any, who controls the Agent within the meaning of the Securities Act or the Exchange Act against any loss, claim, damage, liability
or expense, as incurred, to which the Agent or such officer, employee or controlling person may become subject, under the Securities
Act, the Exchange Act, other federal or state statutory law or regulation, or the laws or regulations of foreign jurisdictions
where Shares have been offered or sold or at common law or otherwise (including in settlement of any litigation), insofar as such
loss, claim, damage, liability or expense (or actions in respect thereof as contemplated below) arises out of or is based upon
(i) any untrue statement or alleged untrue statement of a material fact contained in the Registration Statement, or any amendment
thereto, including any information deemed to be a part thereof pursuant to Rule 430B under the Securities Act, or the omission
or alleged omission therefrom of a material fact required to be stated therein or necessary to make the statements therein not
misleading; (ii) any untrue statement or alleged untrue statement of a material fact contained in any Free Writing Prospectus that
the Company has used, referred to or filed, or is required to file, pursuant to Rule 433(d) of the Securities Act or the Prospectus
(or any amendment or supplement thereto), or the omission or alleged omission therefrom of a material fact necessary in order to
make the statements therein, in the light of the circumstances under which they were made, not misleading, or (iii) or (iii) any
act or failure to act or any alleged act or failure to act by the Agent in connection with, or relating in any manner to, the Ordinary
Shares or the offering contemplated hereby, and which is included as part of or referred to in any loss, claim, damage, liability
or action arising out of or based upon any matter covered by clause (i) or (ii) above, provided that the Company shall not be liable
under this clause (iii) to the extent that a court of competent jurisdiction shall have determined by a final judgment that such
loss, claim, damage, liability or action resulted directly from any such acts or failures to act undertaken or omitted to be taken
by the Agent through its bad faith or willful misconduct, and to reimburse the Agent and each such officer, employee and controlling
person for any and all expenses (including the reasonable and documented fees and disbursements of counsel chosen by the Agent)
as such expenses are reasonably incurred by the Agent or such officer, employee or controlling person in connection with investigating,
defending, settling, compromising or paying any such loss, claim, damage, liability, expense or action; provided, however,
that the foregoing indemnity agreement shall not apply to any loss, claim, damage, liability or expense to the extent, but only
to the extent, arising out of or based upon any untrue statement or alleged untrue statement or omission or
alleged omission made
in reliance upon and in conformity with written information furnished to the Company by the Agent expressly for use in the Registration
Statement, any such Free Writing Prospectus or the Prospectus (or any amendment or supplement thereto), it being understood and
agreed that the only such information furnished by the Agent to the Company consists of the information described in subsection
(b) below. The indemnity agreement set forth in this Section 6(a) shall be in addition to any liabilities that the Company
may otherwise have.
(b) Indemnification
of the Company and its directors and officers. Except in the case of willful misconduct or gross negligence, the Agent agrees
to indemnify and hold harmless the Company, each of its directors, each of its officers who signed the Registration Statement,
and each person, if any, who controls the Company within the meaning of the Securities Act or the Exchange Act, against any loss,
claim, damage, liability or expense, as incurred, to which the Company, or any such director, officer, or controlling person may
become subject, under the Securities Act, the Exchange Act, or other federal or state statutory law or regulation, or at common
law or otherwise (including in settlement of any litigation,), insofar as such loss, claim, damage, liability or expense (or actions
in respect thereof as contemplated below) arises out of or is based upon (i) any untrue statement or alleged untrue statement of
a material fact contained in the Registration Statement, or any amendment thereto, or any omission or alleged omission to state
therein a material fact required to be stated therein or necessary to make the statements therein not misleading or (ii) any untrue
statement or alleged untrue statement of a material fact included or incorporated by reference in any Free Writing Prospectus or
the Prospectus that the Company has used, referred to or filed, or is required to file, pursuant to Rule 433 of the Securities
Act or the Prospectus (or any such amendment or supplement) or the omission or alleged omission to state therein a material fact
necessary in order to make the statements, in the light of the circumstances under which they were made, not misleading, in each
case to the extent, but only to the extent, that such untrue statement or alleged untrue statement or omission or alleged omission
was made in the Registration Statement, Free Writing Prospectus or the Prospectus (or any such amendment or supplement), in reliance
upon and in conformity with information relating to the Agent furnished to the Company by the Agent in writing expressly for use
therein; and to reimburse the Company, or any such director, officer, or controlling person for any and all expenses (including
the fees and disbursements of counsel) as such expenses are incurred by the Company, or any such director, officer, or controlling
person in connection with investigating, defending, settling, compromising or paying any such loss, claim, damage, liability, expense
or action. The Company hereby acknowledges that the only information that the Agent have furnished to the Company expressly for
use in the Registration Statement, any Free Writing Prospectus that the Company has filed, or is required to file, pursuant to
Rule 433(d) of the Securities Act or the Prospectus (or any amendment or supplement to the foregoing) is the information set forth
in the first sentence of the ninth paragraph under the caption “Plan of Distribution” in the Prospectus. The indemnity
agreement set forth in this Section 6(b) shall be in addition to any liabilities that the Agent may otherwise have.
(c) Notifications
and Other Indemnification Procedures. Promptly after receipt by an indemnified party under this Section 6 of notice
of the commencement of any action, such indemnified party will, if a claim in respect thereof is to be made against an indemnifying
party under this Section 6, notify the indemnifying party in writing of the commencement thereof, but the omission to so
notify the indemnifying party will not relieve it from any liability which it may have to any indemnified party for contribution
or otherwise than under the indemnity agreement
contained in this Section
6 or to the extent it is not prejudiced as a proximate result of such failure. In case any such action is brought against any
indemnified party and such indemnified party seeks or intends to seek indemnity from an indemnifying party, the indemnifying party
will be entitled to participate in, and, to the extent that it shall elect, jointly with all other indemnifying parties similarly
notified, by written notice delivered to the indemnified party promptly after receiving the aforesaid notice from such indemnified
party, to assume the defense thereof with counsel reasonably satisfactory to such indemnified party; provided, however,
if the defendants in any such action include both the indemnified party and the indemnifying party and the indemnified party shall
have reasonably concluded based on the advice of counsel that a conflict may arise between the positions of the indemnifying party
and the indemnified party in conducting the defense of any such action or that there may be legal defenses available to it and/or
other indemnified parties which are different from or additional to those available to the indemnifying party, the indemnified
party or parties shall have the right to select separate counsel to assume such legal defenses and to otherwise participate in
the defense of such action on behalf of such indemnified party or parties. Upon receipt of notice from the indemnifying party to
such indemnified party of such indemnifying party’s election to so assume the defense of such action and approval by the
indemnified party of counsel, the indemnifying party will not be liable to such indemnified party under this Section 6 for
any legal or other expenses subsequently incurred by such indemnified party in connection with the defense thereof unless (i) the
indemnified party shall have employed separate counsel in accordance with the proviso to the preceding sentence (it being understood,
however, that the indemnifying party shall not be liable for the fees and expenses of more than one separate counsel (together
with local counsel), representing the indemnified parties who are parties to such action), which counsel (together with any local
counsel) for the indemnified parties shall be selected by the indemnified party (in the case of counsel for the indemnified parties
referred to in Section 6(a) and Section 6(b) above), (ii) the indemnifying party shall not have employed counsel
satisfactory to the indemnified party to represent the indemnified party within a reasonable time after notice of commencement
of the action or (iii) the indemnifying party has authorized in writing the employment of counsel for the indemnified party at
the expense of the indemnifying party, in each of which cases the fees and expenses of counsel shall be at the expense of the indemnifying
party and shall be paid as they are incurred.
(d) Settlements.
The indemnifying party under this Section 6 shall not be liable for any settlement of any proceeding effected without its
written consent, but if settled with such consent or if there be a final judgment for the plaintiff, the indemnifying party agrees
to indemnify the indemnified party against any loss, claim, damage, liability or expense by reason of such settlement or judgment.
Notwithstanding the foregoing sentence, if at any time an indemnified party shall have requested an indemnifying party to reimburse
the indemnified party for fees and expenses of counsel as contemplated by Section 6(b) hereof, the indemnifying party agrees
that it shall be liable for any settlement of any proceeding effected without its written consent if (i) such settlement is entered
into more than 30 days after receipt by such indemnifying party of the aforesaid request; and (ii) such indemnifying party shall
not have reimbursed the indemnified party in accordance with such request prior to the date of such settlement. No indemnifying
party shall, without the prior written consent of the indemnified party, effect any settlement, compromise or consent to the entry
of judgment in any pending or threatened action, suit or proceeding in respect of which any indemnified party is or could have
been a party and indemnity was or could have been sought hereunder by such indemnified party, unless such settlement, compromise
or consent includes an
unconditional release
of such indemnified party from all liability on claims that are the subject matter of such action, suit or proceeding.
(e) Contribution.
If the indemnification provided for in this Section 6 is for any reason held to be unavailable to or otherwise insufficient
to hold harmless an indemnified party in respect of any losses, claims, damages, liabilities or expenses referred to therein, then
each indemnifying party shall contribute to the aggregate amount paid or payable by such indemnified party, as incurred, as a result
of any losses, claims, damages, liabilities or expenses referred to therein (i) in such proportion as is appropriate to reflect
the relative benefits received by the Company, on the one hand, and the Agent, on the other hand, from the offering of the Shares
pursuant to this Agreement; or (ii) if the allocation provided by clause (i) above is not permitted by applicable law, in such
proportion as is appropriate to reflect not only the relative benefits referred to in clause (i) above but also the relative fault
of the Company, on the one hand, and the Agent, on the other hand, in connection with the statements or omissions which resulted
in such losses, claims, damages, liabilities or expenses, as well as any other relevant equitable considerations. The relative
benefits received by the Company, on the one hand, and the Agent, on the other hand, in connection with the offering of the Shares
pursuant to this Agreement shall be deemed to be in the same respective proportions as the total gross proceeds from the offering
of the Shares (before deducting expenses) received by the Company bear to the total commissions received by the Agent. The relative
fault of the Company, on the one hand, and the Agent, on the other hand, shall be determined by reference to, among other things,
whether any such untrue or alleged untrue statement of a material fact or omission or alleged omission to state a material fact
relates to information supplied by the Company, on the one hand, or the Agent, on the other hand, and the parties’ relative
intent, knowledge, access to information and opportunity to correct or prevent such statement or omission.
The amount paid or payable
by a party as a result of the losses, claims, damages, liabilities and expenses referred to above shall be deemed to include, subject
to the limitations set forth in Section 6(b), any legal or other fees or expenses reasonably incurred by such party in connection
with investigating or defending any action or claim. The provisions set forth in Section 6(b) with respect to notice of
commencement of any action shall apply if a claim for contribution is to be made under this Section 6(e); provided, however,
that no additional notice shall be required with respect to any action for which notice has been given under Section 6(b)
for purposes of indemnification.
The Company and the Agent agree that it would
not be just and equitable if contribution pursuant to this Section 6(e) were determined by pro rata allocation or by any
other method of allocation which does not take account of the equitable considerations referred to in this Section 6(e).
Notwithstanding the
provisions of this Section 6(e), the Agent shall not be required to contribute any amount in excess of the agent fees received
by the Agent in connection with the offering contemplated hereby. No person guilty of fraudulent misrepresentation (within the
meaning of Section 11(f) of the Securities Act) shall be entitled to contribution from any person who was not guilty of such fraudulent
misrepresentation. For purposes of this Section 6(e), each officer and employee of the Agent and each person, if any, who
controls the Agent within the meaning of the Securities Act or the Exchange Act shall have the same rights to contribution as
the Agent, and each director of the Company,
each officer of the Company who signed the Registration Statement, and each person, if any, who controls the Company within the
meaning of the Securities Act and the Exchange Act shall have the same rights to contribution as the Company.
Section 7. TERMINATION &
SURVIVAL
(a) Term.
Subject to the provisions of this Section 7, the term of this Agreement shall continue from the date of this Agreement until
the end of the Agency Period, unless earlier terminated by the parties to this Agreement pursuant to this Section 7.
(b) Termination;
Survival Following Termination.
| (i) | Either party may terminate this Agreement prior to the end of the Agency Period, by giving written
notice as required by this Agreement, upon three (3) Trading Days’ notice to the other party; provided that, (A) if the Company
terminates this Agreement after the Agent confirms to the Company any sale of Shares, the Company shall remain obligated to comply
with Section 3(b)(v) with respect to such Shares and (B) Section 2, Section 6, Section 7 and Section 8 shall survive termination of this Agreement. If termination shall occur prior to the Settlement Date for any sale of Shares,
such sale shall nevertheless settle in accordance with the terms of this Agreement. |
| (ii) | In addition to the survival provision of Section 7(b)(i), the respective indemnities, agreements,
representations, warranties and other statements of the Company, of its officers and of the Agent set forth in or made pursuant
to this Agreement will remain in full force and effect, regardless of any investigation made by or on behalf of the Agent or the
Company or any of its or their partners, officers or directors or any controlling person, as the case may be, and, anything herein
to the contrary notwithstanding, will survive delivery of and payment for the Shares sold hereunder and any termination of this
Agreement. |
Section 8. MISCELLANEOUS
(a) Press
Releases and Disclosure. The Company may issue a press release and inside information notification describing the material
terms of the transactions contemplated hereby as soon as practicable following the date of this Agreement, and may file with the
Commission a report on Form 6-K (or Form 8-K if applicable), with this Agreement attached as an exhibit thereto, describing the
material terms of the transactions contemplated hereby, and the Company shall consult with the Agent prior to making such disclosures,
and the parties hereto shall use all commercially reasonable efforts, acting in good faith, to agree upon a text for such disclosures
that is reasonably satisfactory to all parties hereto. No party hereto shall issue thereafter any press release or like public
statement (including, without limitation, any disclosure required in reports filed with the Commission pursuant to the Exchange
Act) related to this Agreement or any of the transactions contemplated hereby without the prior written approval of the other party
hereto, except as may be necessary or appropriate in the reasonable opinion of the party seeking to make disclosure to comply with
the requirements of applicable law or stock exchange rules. If any such press release or like public statement is so required,
the party making such disclosure shall consult
with the other party
prior to making such disclosure, and the parties shall use all commercially reasonable efforts, acting in good faith, to agree
upon a text for such disclosure that is reasonably satisfactory to all parties hereto.
(b) No
Advisory or Fiduciary Relationship. The Company acknowledges and agrees that (i) the transactions contemplated by this
Agreement, including the determination of any fees, are arm’s-length commercial transactions between the Company and the
Agent, (ii) when acting as a principal under this Agreement, the Agent is and has been acting solely as a principal is not the
agent or fiduciary of the Company, or its shareholders, creditors, employees or any other party, (iii) the Agent has not assumed
nor will assume an advisory or fiduciary responsibility in favor of the Company with respect to the transactions contemplated hereby
or the process leading thereto (irrespective of whether the Agent has advised or is currently advising the Company on other matters)
and the Agent does not have any obligation to the Company with respect to the transactions contemplated hereby except the obligations
expressly set forth in this Agreement, (iv) the Agent and its Affiliates may be engaged in a broad range of transactions that involve
interests that differ from those of the Company, and (v) the Agent has not provided any legal, accounting, regulatory or tax advice
with respect to the transactions contemplated hereby and the Company has consulted its own legal, accounting, regulatory and tax
advisors to the extent it deemed appropriate.
(c) Research
Analyst Independence. The Company acknowledges that the Agent’s research analysts and research departments are required
to and should be independent from their respective investment banking divisions and are subject to certain regulations and internal
policies, and as such the Agent’s research analysts may hold views and make statements or investment recommendations and/or
publish research reports with respect to the Company or the offering that differ from the views of their respective investment
banking divisions. The Company understands that the Agent is a full service securities firm and as such from time to time, subject
to applicable securities laws, may effect transactions for its own account or the account of its customers and hold long or short
positions in debt or equity securities of the companies that may be the subject of the transactions contemplated by this Agreement.
(d) Notices.
All communications hereunder shall be in writing and shall be mailed, hand delivered or telecopied and confirmed to the parties
hereto as follows:
If
to the Agent:
Jefferies LLC
520 Madison Avenue
New York, NY 10022
Attention: General Counsel
with a copy (which shall not constitute
notice) to:
Paul Hastings LLP
MetLife Building
200 Park Avenue
New
York, New York 10166
Attention: Siavosh Salimi and William Magioncalda
If to the Company:
Alvotech
9, Rue de Bitbourg
L-1273 Luxembourg
Grand Duchy of Luxembourg
Attention: Chief Financial Officer.
with a copy (which shall not constitute
notice) to:
Cooley LLP
55 Hudson Yards
New York, New York 10001
Attention: Daniel Goldberg and Divakar Gupta
Any party hereto may change the address
for receipt of communications by giving written notice to the others in accordance with this Section 8(d).
(e) Successors.
This Agreement will inure to the benefit of and be binding upon the parties hereto, and to the benefit of the employees,
officers and directors and controlling persons referred to in Section 6, and in each case their respective successors, and
no other person will have any right or obligation hereunder. The term “successors” shall not include any purchaser
of the Shares as such from the Agent merely by reason of such purchase.
(f) Partial
Unenforceability. The invalidity or unenforceability of any Article, Section, paragraph or provision of this Agreement
shall not affect the validity or enforceability of any other Article, Section, paragraph or provision hereof. If any Article, Section,
paragraph or provision of this Agreement is for any reason determined to be invalid or unenforceable, there shall be deemed to
be made such minor changes (and only such minor changes) as are necessary to make it valid and enforceable.
(g) Governing
Law Provisions. This Agreement shall be governed by and construed in accordance with the internal laws of the State
of New York applicable to agreements made and to be performed in such state. Any legal suit, action or proceeding arising out of
or based upon this Agreement or the transactions contemplated hereby (“Related Proceedings”) may be instituted
in the federal courts of the United States of America located in the Borough of Manhattan in the City of New York or the courts
of the State of New York in each case located in the Borough of Manhattan in the City of New York (collectively, the “Specified
Courts”), and each party irrevocably submits to the exclusive jurisdiction (except for proceedings instituted in regard
to the enforcement of a judgment of any such court (a “Related Judgment”), as to which such jurisdiction is
non-exclusive) of such courts in any such suit, action or proceeding. Service of any process, summons, notice or document by mail
to such party’s address set forth above shall be effective service of process for any suit, action or other proceeding brought
in any such court. The parties irrevocably and unconditionally waive any objection to the laying of venue of any suit,
action or other proceeding
in the Specified Courts and irrevocably and unconditionally waive and agree not to plead or claim in any such court that any such
suit, action or other proceeding brought in any such court has been brought in an inconvenient forum. The Company irrevocably appoints
Alvotech USA Inc. as its agent to receive service of process or other legal summons for purposes of any such suit, action or proceeding
that may be instituted in any state or federal court in the City and County of New York. With respect to any related proceeding,
each party irrevocably waives, to the fullest extent permitted by applicable law, all immunity (whether on the basis of sovereignty
or otherwise) from jurisdiction, service of process, attachment (both before and after judgment) and execution to which it might
otherwise be entitled in the Specified Courts, and with respect to any Related Judgment, each party waives any such immunity in
the Specified Courts or any other court of competent jurisdiction, and will not raise or claim or cause to be pleaded any such
immunity at or in respect of any such related proceeding or Related Judgment, including, without limitation, any immunity pursuant
to the United States Foreign Sovereign Immunities Act of 1976, as amended.
(h) Judgment
Currency. The obligations of the Company pursuant to this Agreement in respect of any sum due to the Agent shall, notwithstanding
any judgment in a currency other than U.S. dollars, not be discharged until the first business day, following receipt by the Agent
of any sum adjudged to be so due in such other currency, on which (and only to the extent that) the Agent may in accordance with
normal banking procedures purchase U.S. dollars with such other currency; if the U.S. dollars so purchased are less than the sum
originally due to the Agent hereunder, the Company agrees, as a separate obligation and notwithstanding any such judgment, to indemnify
the Agent against such loss.
(i) General
Provisions. This Agreement constitutes the entire agreement of the parties to this Agreement and supersedes all prior
written or oral and all contemporaneous oral agreements, understandings and negotiations with respect to the subject matter hereof.
This Agreement may be executed in two or more counterparts, each one of which shall be an original, with the same effect as if
the signatures thereto and hereto were upon the same instrument, and may be delivered by facsimile transmission or by electronic
delivery of a portable document format (PDF) file (including any electronic signature covered by the U.S. federal ESIGN Act of
2000, Uniform Electronic Transactions Act, the Electronic Signatures and Records Act or other applicable law, e.g., www.docusign.com).
This Agreement may not be amended or modified unless in writing by all of the parties hereto, and no condition herein (express
or implied) may be waived unless waived in writing by each party whom the condition is meant to benefit. The Article and Section
headings herein are for the convenience of the parties only and shall not affect the construction or interpretation of this Agreement.
[Signature Page Immediately Follows]
If the foregoing is
in accordance with your understanding of our agreement, kindly sign and return to the Company the enclosed copies hereof, whereupon
this instrument, along with all counterparts hereof, shall become a binding agreement in accordance with its terms
| |
Very truly yours, |
| |
|
| |
ALVOTECH |
| |
|
|
| |
By: |
/s/ Joel Morales |
| |
|
Name: Joel Morales |
| |
|
Title: Chief Executive Officer |
The foregoing Agreement is hereby confirmed
and accepted by the Agent in New York, New York as of the date first above written.
JEFFERIES LLC
| By: |
/s/ Michael Magarro |
|
| |
Name: Michael Magarro |
|
| |
Title: Managing Director |
|
EXHIBIT A
ISSUANCE NOTICE
Alvotech
société anonyme
9, rue de Bitbourg, L-1273 Luxembourg
RCS Luxembourg : B 258.884
(the “Company”)
[Date]
Jefferies LLC
520 Madison Avenue
New York, New York 10022
Attn: [__________]
Reference is made to the Open Market Sale
Agreement between the Company and Jefferies LLC (the “Agent”) dated as of June [●], 2024. The Company
confirms that all conditions to the delivery of this Issuance Notice are satisfied as of the date hereof.
Date of Delivery of Issuance Notice (determined pursuant to
Section 3(b)(i)):
Issuance Amount (equal to the total Sales Price for such Shares):
| |
$ |
|
|
| |
|
|
|
| Number of days in selling period: |
|
|
|
| |
|
|
|
| First date of selling period: |
|
|
|
| |
|
|
|
| Last date of selling period: |
|
|
|
Settlement Date(s) if other than standard T+1 settlement1:
Floor Price Limitation (in no event less
than $1.00 without the prior written consent of the Agent, which consent may be withheld in the Agent’s sole discretion):
$ ____ per Share.
| Type of Shares: |
[New Shares / Treasury Shares] |
|
Bank Account:
1
To take (different) public holidays in U.S. and Luxembourg into account.
EXHIBIT B
Jefferies LLC
520 Madison Avenue
New York, New York 10022
[Date]
Alvotech
9, rue de Bitbourg, L-1273 Luxembourg
RCS Luxembourg : B 258884
Reference is made to your Issuance Notice
dated [●]. You have elected an issuance of New Shares. Capitalized terms herein shall have the same meaning as in the Open
Market Sale AgreementSM, dated [●] between the Company and Jefferies LLC.
We hereby subscribe for [●] ordinary
shares of the Company (the “Shares”) for an aggregate subscription price of USD [0.01] per Share, to be fully
paid up in cash.
This subscription certificate will remain
in force for a period of [20] calendar days as from (and including) the date of signature of the present certificate and shall
expire automatically after the passage of such [20] calendar days if the corresponding capital increase of the Company has not
been effected prior thereto.
Schedule A
Notice Parties
The Company
Joel Morales [***]
Tanya Zharov [***]
The Agent
Michael Magarro
EXHIBIT C
FORM OF OFFICER’S CERTIFICATE PURSUANT
TO SECTION 4(o)
The undersigned, the duly qualified
and elected Chief [Executive/Financial] Officer of Alvotech, a public limited liability company (société anonyme)
incorporated and existing under the laws of the Grand Duchy of Luxembourg, having its registered office at 9, rue de Bitbourg,
L-1273 Luxembourg, and registered with the Luxembourg Register of Commerce and Companies (R.C.S. Luxembourg) under number
B258884 (the “Company”), does hereby certify in such capacity and on behalf of the Company, pursuant to Section
4(o) of the Open Market Sale AgreementSM, dated [•], 2024, between the Company and Jefferies LLC (the “Sales
Agreement”), that to the knowledge of the undersigned:
(i) The representations
and warranties of the Company in Section 2 of the Sales Agreement are true and correct on and as of the date hereof with the same
force and effect as if expressly made on and as of the date hereof; provided, however, that such representations and warranties
are qualified by the disclosure included or incorporated by reference in the Registration Statement and Prospectus (including any
documents incorporated by reference therein and any supplements thereto); and
(ii) The Company has complied
with all agreements and satisfied all conditions on its part to be performed or satisfied pursuant to the Sales Agreement at or
prior to the date hereof.
Cooley LLP, Arendt &
Medernach SA and Paul Hastings LLP are entitled to rely on this certificate in connection with the respective opinions such firms
are rendering pursuant to the Sales Agreement. Capitalized terms used herein without definition shall have the meanings given to
such terms in the Sales Agreement.
[The Remainder of This Page Is Intentionally
Left Blank]
IN WITNESS WHEREOF, the undersigned
has caused this certificate to be executed as of the date first written above.
| |
|
|
|
|
| |
ALVOTECH |
|
| |
|
|
|
|
| |
By: |
|
|
|
| |
|
|
|
|
| |
Name: |
|
|
| |
|
|
|
|
| |
Title: |
|
|
Exhibit 5.1
| |
To
Alvotech
9, rue de Bitbourg,
L - 1273 Luxembourg,
Grand Duchy of Luxembourg
(the “Company”)
Luxembourg, 14
June 2024
|
AO/YBA – 016843-70016.41407908
Alvotech – Prospectus Supplement
Dear Madam, dear Sir,
We have acted as Luxembourg legal advisers
to Alvotech, a company existing under the laws of the Grand Duchy of Luxembourg as a société anonyme (formerly
a société par actions simplifiée), with its registered office at 9, rue de Bitbourg, L-1273 Luxembourg,
Grand Duchy of Luxembourg, and registered with the Luxembourg Register of Commerce and Companies (Registre de Commerce et des
Sociétés à Luxembourg) (the “RCS”) under number B 258884 in connection with the
preparation and filing of a prospectus supplement (the “Prospectus
Supplement”). The Prospectus Supplement supplements a registration statement on Form F-3 that the Company filed with
the U.S. Securities and Exchange Commission on 20 October 2023 (the “Registration Statement”). The Registration
Statement relates to the proposed offer and sale by the Company from time to time, as set forth therein and as shall be set
forth in one or more supplements to the prospectus, of an aggregate initial offering price of up to $100,000,000, of any or all
of the following instruments to be issued in the form of securities and covered by the Registration Statement (collectively, the
“Securities”): (a) ordinary shares of
the Company with a nominal value of $0.01 per share (the “Ordinary Shares”);
(b) debt securities of the Company (the “Debt Securities”); (c)
rights to purchase any of the Company’s Securities or any combination thereof (the “Rights”);
(d) warrants to purchase Ordinary Shares (the “Warrants”); and
(e) units comprising any combination of Ordinary Shares, Warrants, Debt Securities and/or Rights.
The
Prospectus Supplement relates to the offering, issuance and sale of an amount of Ordinary Shares (the “Placement Shares”)
with an aggregate offering price of up to $75,000,000 that may be issued
and
sold under a sales agreement to be entered into between the Company and Jefferies LLC on or around 14 June 2024 (the “Sales Agreement”).
| 1.1. | In arriving to the opinions expressed below, we have examined and relied exclusively on the documents
(the “Documents”) identified in Appendix A hereto. |
| 1.2. | We express no opinion with respect to any laws, rules or regulations other than Luxembourg law.
We express no opinion (a) on public international law or on the rules promulgated under any treaty or by any treaty organisation
or on any accounting, criminal, data protection or tax laws, rules or regulations of any jurisdiction (including Luxembourg) or
(b) with respect to the effect of any laws, rules or regulations other than Luxembourg law even in cases where, under Luxembourg
law, a foreign law, rule or regulation should be applied, and we therefore assume that no provisions of any foreign laws, rules
or regulations affect, qualify or have any bearing on this Opinion. |
| 1.3. | A reference to a convention, law, rule or regulation in this Opinion is to be construed as a reference
to such convention, law, rule or regulation as amended or re-enacted. |
For the purpose of this Opinion, we have
assumed, and we have not verified independently:
| 2.1. | that each signature (whether manuscript or electronic) is the genuine signature of the individual
concerned and was affixed or inserted by such individual concerned or authorized to be inserted in the relevant document by the
individual concerned; |
| 2.2. | the completeness and conformity to originals of all Documents supplied to us as drafts, certified,
photostatic, scanned, electronically transmitted copies or other copies of the documents reviewed and the authenticity of the originals
of such documents and the conformity to originals of the latest drafts reviewed by us and the completeness and correctness of the
representations and statements made therein; |
| 2.3. | that there have been no amendments to the Documents in the form delivered to us for the purpose
of this Opinion, and, to the extent provided in draft form, the Documents will be signed by the parties thereto in the form delivered to us on or around
the date hereof and there will be no amendments to such Documents prior to their execution which would have a bearing on this Opinion; |
| 2.4. | that there is no other resolution, decision, agreement or undertaking and no other arrangement
(whether legally binding or not) which renders any of the Documents or information reviewed or provided to us inaccurate, incomplete
or misleading or which affects the conclusions stated in this Opinion and that the Documents reviewed accurately record the whole
of the terms agreed between the parties thereto relevant to this Opinion; |
| 2.5. | that the Company does not meet the criteria for the commencement of any insolvency proceedings
such as administrative dissolution without liquidation (dissolution administrative sans liquidation), bankruptcy (faillite),
insolvency, winding-up, liquidation, moratorium, suspension of payment (sursis de paiement), conciliation (conciliation),
reorganisation |
| | procedure in the form of a mutual agreement (réorganisation par accord amiable),
judicial reorganisation proceedings in the form of a mutual agreement (réorganisation judiciaire par accord amiable),
a collective agreement (réorganisation judiciaire par accord collectif) or a transfer by court order (réorganisation
judiciaire par transfert par décision de justice), fraudulent conveyance, general settlement with creditors, reorganisation
or similar measures, orders or proceedings affecting the rights of creditors generally; |
| 2.6. | that the Company may deliver newly issued Ordinary Shares (the “New Shares”)
and / or Treasury Shares (as defined in Appendix A, and together with the New Shares, the “Shares”) under the
terms of the Sales Agreement; |
| 2.7. | that the board of directors of the Company and/or its delegate, as applicable, (i) in case of New
Shares will adopt one or several resolutions to issue and deliver the New Shares, have the issuance acknowledged by a Luxembourg
notary, and take all necessary steps and comply with applicable requirements at the time to give full effect to the issuance of
the New Shares in accordance with the Sales Agreement and Luxembourg law or (ii) in case of Treasury Shares, will hold, acquire
or purchase for delivery a sufficient number of Treasury Shares to settle its obligations under the Sales Agreement; |
| 2.8. | that all conditions precedent in the Documents for the transactions contemplated are or will be
satisfied prior to the issuance of any New Shares, as applicable, in accordance with the Registration Statement and the Prospectus
Supplement; |
| 2.9. | that the Sales Agreement is and will remain until the issuance and/or sale of Shares legal valid
and binding as a matter of applicable law thereunder; |
| 2.10. | that all approvals, authorisations, clearances, consents, filings or licenses, orders or registrations
required from any governmental, public, regulatory or other agencies, authorities, bodies or other persons outside Luxembourg have
been obtained or fulfilled and are and will remain in full force and effect; that all steps outside Luxembourg and requirements
outside Luxembourg affecting the legality, validity, binding effect and enforceability of the Documents (and the transactions contemplated
therein) and that all conditions to which the transactions under the Documents are subject have been satisfied or, in case of the
Shares, will be satisfied prior to the issuance of Shares; |
| 2.11. | the existence, capacity, power and authority of each of the parties to the Documents (other than
the Company) to enter into the Documents to which it is a party and perform its obligations under those Documents and that each
individual purporting to have signed the Documents has in fact signed the Documents and had legal capacity when he or she signed
and each individual intended to sign the Documents will in fact sign the Documents and will have legal capacity when he or she
signs; |
| 2.12. | that there will be no amendment to the authorised share capital of the Company or the warrant terms
and conditions which would adversely affect the issue of the Shares and the conclusions stated in this Opinion; |
| 2.13. | that the Shares will not be offered to the public or admitted to trading on a regulated market
in circumstances where the obligation to publish a prospectus in accordance with Regulation |
| | (EU) 2017/1129 of the European Parliament and of the Council of 14 June 2017 on the prospectus
to be published when securities are offered to the public or admitted to trading on a regulated market, as amended and/or the Luxembourg
law of 16 July 2019 relating to prospectuses for securities, as amended, arises (without prejudice to applicable securities laws
in any jurisdiction other than Luxembourg where the Shares have been or will be marketed, offered or sold); |
| 2.14. | that any stabilisation measures or other transactions with a view to supporting the market price
of the Shares will only be carried out, in accordance with the provisions of Article 5 para. 4 and 5 of the Regulation (EU) No
596/2014 of the European Parliament and of the Council of 16 April 2014 on market abuse (market abuse regulation) (the “Market
Abuse Regulation”) in conjunction with Articles 5 through 8 of the Commission Delegated Regulation (EU) 2016/1052 of
8 March 2016 supplementing the Market Abuse Regulation with regard to regulatory technical standards for the conditions applicable
to buy-back programmes and stabilisation measures, without prejudice to applicable securities laws in jurisdictions other than
Luxembourg where the Shares are listed and admitted to trading; |
| 2.15. | that the New Shares will be issued in registered form (actions nominatives); |
| 2.16. | that the entry into the Documents and the performance of any rights and obligations under the Documents
are in the best corporate interests (intérêt social) of the Company and that the head office (administration
centrale), the place of effective management (siege de direction effective), and, for the purposes of the regulation
(EU) 2015/848 of the European Parliament and of the Council of 20 May 2015 on insolvency proceedings (recast), the center
of main interests (centre des intérêts principaux) of the Company is located at the place of its registered
office (siege statutaire) in Luxembourg. |
This Opinion is given
on the basis that it is governed by and construed in accordance with Luxembourg law only and is subject to the exclusive jurisdiction
of the courts of Luxembourg. We express no opinion on accounting, economic, financial, monetary, policy and tax aspects. On the
basis of the assumptions set out above and subject to the qualifications set out below and to any factual matters, documents or
events not disclosed to us, we are of the opinion that:
| 3.1. | The Company is a public limited company (société anonyme) and has been incorporated
for an unlimited duration and is validly existing under the laws of Luxembourg. |
| 3.2. | In case of Treasury Shares, the Treasury Shares have been validly issued and are fully paid up
and non-assessable (meaning that the holder of such Shares shall not be liable, solely because of his/her/its shareholder status,
for additional payments to the Company or the Company’s creditors). |
| 3.3. | In case of New Shares, and subject to the accomplishment of all the requirements and formalities
set out in the Company’s articles of association, Luxembourg law and the Sales Agreement, the Shares will be validly issued,
fully paid up and non-assessable (meaning no further payments will have to be made thereon), free and clear of any pledge, lien, |
| | encumbrance, security interest or other claim, including any staturoy or contractual preemptive
rights, resale rights, rights of first refusal or other similar rights. |
The opinions expressed
herein are subject to the following qualifications:
| 4.1. | Luxembourg legal concepts are expressed in English terms and not in their original French terms.
The concepts in question may not be identical to the concepts described by the same English terms as they exist in the laws, rules
and regulations of other jurisdictions; |
| 4.2. | the opinions expressed herein are subject to all limitations by reason of bankruptcy proceedings
(faillite), suspension of payment (sursis de paiement), judicial reorganisation proceedings (procédures
de réorganisation judiciaire), judicial decisions regarding the appointment of a provisional administrator (administrateur
provisoire), judicial decisions taken by foreign judicial authorities concerning insolvency, voluntary arrangements or any
similar proceedings in accordance with the Regulation (EU) 2015/848 of the European Parliament and of the Council of 20 May 2015
on insolvency proceedings (recast), judicial decisions reclassifying administrative dissolution without liquidation (dissolution
administrative sans liquidation) procedures, or decisions by the manager of the Luxembourg Trade and Companies Register to
open or close administrative dissolution without liquidation (dissolution administrative sans liquidation) or similar orders
or proceedings affecting the rights of creditors generally; |
| 4.3. | deeds (actes) or extracts of deeds (extraits d’actes) and other indications relating
to the Company and which, under Luxembourg law, must be published on the RESA (as defined below) (and which mainly concern
acts relating to the incorporation, the formation, the functioning, the appointment of managers or directors and the liquidation
of the relevant company as well as amendments, if any, to the articles of association) will only be enforceable against third parties
after they have been published on the RESA except where the Company proves that such third parties had previous knowledge of the
deeds or extracts of deeds. Third parties may rely on deeds or extracts of deeds prior to their publication. For the fifteen days
following the publication, the deeds or extracts of deeds will not be enforceable against third parties who prove that it was impossible
for them to have had knowledge of the deeds or extracts of deeds within that time; |
| 4.4. | the opinions set out in this Opinion are limited
to the laws, including the rules and regulations, as in effect on the date of this Opinion. |
| 5.1. | This Opinion is issued solely for the purposes of the filing of the Prospectus Supplement. |
| 5.2. | It may not be used, circulated, quoted, referred
to or relied upon for any other purpose without our written consent. We hereby consent to filing of this opinion as an exhibit
to the Prospectus Supplement and to the reference to our firm under the caption “Legal Matters” in the Prospectus Supplement.
This opinion is strictly limited to the matters stated in it and is given |
| | on the date set out on page 1; we have no obligation to update the opinion or inform of any changes
in law following such date. |
| 5.3. | This Opinion is issued by and signed on behalf of Arendt & Medernach SA, admitted to practice
in the Grand-Duchy of Luxembourg and registered on list V of the lawyers of the Luxembourg bar association. |
Yours faithfully,
By and on behalf of Arendt & Medernach
SA
/s/ Alexander Olliges
Alexander Olliges
Partner
APPENDIX A – DOCUMENTS
| 1. | A scanned copy of the draft Sales Agreement received on 14 June 2024 at 3:15 a.m. CEST. |
| 2. | A scanned copy of the Registration Statement filed on 20 October 2023. |
| 3. | A scanned copy of the consolidated articles of association of the Company dated 12 March 2024 (the
“Articles”). |
| 4. | An extract dated 14
June 2024 and issued in electronic form by the RCS in respect of
the Company. |
| 5. | A certificate of non-registration
of a judicial decision (certificat de non-inscription d’une décision
judiciaire) dated 14 June 2024 and
issued in electronic form by the RCS in respect of the Company. |
| 6. | A scanned copy of the minutes of the resolution of the board of directors
of the Company dated 7 June 2024. |
| 7. | A scanned copy of the notarial deed of acknowledgement of capital increase by an amount of two
million seven hundred seven thousand two hundred sixteen US dollars and seventy-two cents (USD 2,707,216.72) through the issuance
of twenty-seven million seventy-two thousand one hundred and sixty-seven (27,072,167) shares (the “Initial Treasury
Shares”) dated 4 July 2022. |
| 8. | A scanned copy of the signed subscription form signed by Alvotech Manco ehf. dated 4 July 2022. |
| 9. | A scanned copy of the signed minutes of the meeting of the board of directors of the Company dated
1 March 2023. |
| 10. | A scanned copy of the signed decision of the delegates appointed by the board of directors of the
Company dated 28 March 2023 |
| 11. | A scanned copy of the notarial deed of acknowledgement of capital increase by an amount of one
hundred forty thousand fifty-seven Us dollars and ninety cents (USD 140,057.90) through the issuance of fourteen million five thousand
seven hundred ninety (14,005,790) shares (the “First Subsequent Treasury Shares”) dated 28 March 2023. |
| 12. | A scanned copy of the signed subscription form signed by Alvotech Manco ehf. dated 28 March 2023. |
| 13. | A scanned copy of the signed confirmation certificate of the delegates appointed by the board of
directors dated 28 March 2023. |
| 14. | A scanned copy of the notarial deed of acknowledgement of capital increase by an amount of one
hundred thirty thousand US dollars (USD 130,000) through the issuance of thirteen million (13,000,000) shares (the “Second
Subsequent Treasury Shares” and, together with the Initial Treasury Shares and the First Subsequent Treasury
Shares, the “Treasury Shares”) dated 12 March 2024. |
| 15. | A scanned copy of the signed subscription form signed by Alvotech Manco ehf. dated 11 March 2024. |
| 16. | A scanned copy of the circular resolutions of the board of directors of the Company dated
7 March 2024. |
Exhibit 99.1
Cautionary Note Regarding Forward Looking Statements
This Exhibit
contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as
amended. Forward-looking statements generally relate to future events or the future financial operating performance of Alvotech
and may include, for example, Alvotech’s expectations regarding its ability to satisfy conditions precedent to close the
transaction and draw down the Term Loans under the Loan Agreement, to comply with the covenants of the Loan Agreement and to exercise
its rights under the Loan Agreement, the expected use of proceeds from the Loan Agreement, potential future financings or strategic
transactions, Alvotech’s expectations regarding competitive advantages, business prospects and opportunities, including pipeline
product development, future plans and intentions, results, level of activities, performance, goals or achievements or other future
events, regulatory submissions, review and interactions, the potential approval and commercial launch of its product candidates,
the timing of regulatory approval, market launches, and partnership and distribution agreements. In some cases, you can identify forward-looking
statements by terminology such as “may”, “should”, “expect”, “intend”, “will”,
“estimate”, “anticipate”, “believe”, “predict”, “potential”, “aim”
or “continue”, or the negatives of these terms or variations of them or similar terminology. Such forward-looking statements
are subject to risks, uncertainties, and other factors which could cause actual results to differ materially from those expressed
or implied by such forward-looking statements. These forward-looking statements are based upon estimates and assumptions that,
while considered reasonable by Alvotech and its management, are inherently uncertain and are inherently subject to risks, variability,
and contingencies, many of which are beyond Alvotech’s control. Factors that may cause actual results to differ materially
from current expectations include, but are not limited to: (1) the ability to raise substantial additional funding, which may not
be available on acceptable terms or at all; (2) the ability to maintain stock exchange listing standards; (3) changes in applicable
laws or regulations; (4) the possibility that Alvotech may be adversely affected by other economic, business, and/or competitive
factors; (5) Alvotech’s estimates of expenses and profitability; (6) Alvotech’s ability to develop, manufacture and
commercialize the products and product candidates in its pipeline; (7) actions of regulatory authorities, which may affect the
initiation, timing and progress of clinical studies or future regulatory approvals or marketing authorizations; (8) the ability
of Alvotech or its partners to enroll and retain patients in clinical studies; (9) the ability of Alvotech or its partners to gain
approval from regulators for planned clinical studies, study plans or sites; (10) the ability of Alvotech’s partners to conduct,
supervise and monitor existing and potential future clinical studies, which may impact development timelines and plans; (11) Alvotech’s
ability to obtain and maintain regulatory approval or authorizations of its products, including the timing or likelihood of expansion
into additional markets or geographies; (12) the success of Alvotech’s current and future collaborations, joint ventures,
partnerships, distribution or licensing arrangements; (13) Alvotech’s ability, and that of its commercial partners, to execute their commercialization
strategy for approved products; (14) Alvotech’s ability to manufacture sufficient commercial supply of its approved products;
(15) the outcome of ongoing and future litigation regarding Alvotech’s products and product candidates; (16) the impact of
worsening macroeconomic conditions, including rising inflation and interest rates and general market conditions, conflicts in Ukraine,
the Middle East and other global geopolitical tension, on the Company’s business, financial position, strategy and anticipated
milestones; and (17) other risks and uncertainties set forth in the sections entitled “Risk Factors” and “Cautionary
Note Regarding Forward-Looking Statements” in documents that Alvotech may from time to time
file or furnish
with the SEC. There may be additional risks that Alvotech does not presently know or that Alvotech currently believes are immaterial
that could also cause actual results to differ from those contained in the forward-looking statements. Nothing in this Exhibit
should be regarded as a representation by any person that the forward-looking statements set forth herein will be achieved or that
any of the contemplated results of such forward-looking statements will be achieved. You should not place undue reliance on forward-looking
statements, which speak only as of the date they are made. Alvotech does not undertake any duty to update these forward-looking
statements or to inform the recipient of any matters of which any of them becomes aware of which may affect any matter referred
to in this Exhibit.
Company Overview
We
are a vertically integrated biotech company focused solely on the development and manufacture of biosimilar medicines for patients
worldwide. Our purpose is to improve the health and quality of life of patients around the world by improving access to proven
treatments for various diseases. Since our inception, we have built our company with key characteristics we believe will help us
capture the substantial global market opportunity in biosimilars: a leadership team that has brought numerous successful biologics
and biosimilars to market around the world; a purpose-built biosimilars research and development and manufacturing platform; commercial
partnerships in global markets; and a diverse, expanding portfolio and pipeline addressing many of the biggest disease areas and
health challenges globally.
We
have built a portfolio and pipeline comprising two approved products and nine product candidates covering a variety of therapeutic
areas, including immunology, ophthalmology, bone disease and cancer.
| · | Our lead program, AVT02,
a high concentration formulation
biosimilar to Humira, has
received regulatory approval
in over 50 markets and
has been launched in over
20 markets globally, including
in select European countries
under the trade name Hukyndra
and in Canada under the
trade name SIMLANDI. In
the first quarter of 2024,
the FDA approved our biologics
license application (“BLA”)
supporting interchangeability
for AVT02 in the United
States for the treatment
of adult rheumatoid arthritis,
juvenile idiopathic arthritis,
adult psoriatic arthritis,
adult ankylosing spondylitis,
Crohn’s disease,
adult ulcerative colitis,
adult plaque psoriasis,
adult hidradenitis suppurativa
and adult uveitis. We launched
AVT02 under the trade name
SIMLANDI in the United
States in the second quarter
of 2024. Additionally,
in the second quarter of
2024, we entered into a
strategic partnership agreement
with Quallent Pharmaceuticals
(“Quallent”),
a subsidiary of the Cigna
group, to distribute AVT02
under Quallent’s
private label in the United
States, and we entered
into an agreement with
STADA to extend its commercial
rights to AVT02 to the
Commonwealth of Independent
States (CIS) countries. |
| · | For AVT04, a proposed
biosimilar to Stelara (ustekinumab),
our commercialization partner
Fuji Pharma received regulatory
approval in Japan in the
third quarter of 2023 and
our commercialization partner
JAMP Pharma received regulatory
approval in Canada in the
fourth quarter of 2023.
Our commercialization partner
STADA received approval
for the European Economic
Area (the “EEA”)
in January 2024. AVT04
was launched under the
trade name Jamteki in Canada
on March 1, 2024, and we
expect it to be launched
in Japan in the second
quarter of 2024 and in
select European markets
starting in the third quarter
of 2024. In the second
quarter of 2024, the FDA
approved AVT04 for marketing
in the United States as
a biosimilar to Stelara
under the tradename Selarsdi,
which is expected to be
launched in February 2025.
Additionally, in the second
quarter of 2024, we entered
into an agreement with
STADA to extend its commercial
rights to AVT04 to the
Commonwealth of Independent
States (CIS) countries |
| · | We are in advanced
stages of development for
AVT03, a biosimilar candidate
to Prolia / Xgeva (denosumab),
AVT05, a biosimilar candidate
to Simponi and Simponi
Aria (golimumab), and AVT06,
a biosimilar candidate
to Eylea (aflibercept).
We expect to file marketing
applications and BLAs for
these biosimilar candidates
in 2024. In the second
quarter of 2024, we signed
a commercial partnership
agreement with Dr. Reddy’s
Laboratories Ltd. for the
commercialization of AVT03
with exclusive rights for
the United States and semi-exclusive
rights for Europe and United
Kingdom. In addition, in
the second quarter of 2024,
we entered into an agreement
with STADA to extend the
partnership to cover AVT03
pursuant to which STADA
will become marketing authorization
holder, upon approval of
AVT03, and will assume
semi-exclusive commercial
rights in Europe, including
Switzerland and the UK,
as well as exclusive commercial
rights in selected countries
in Central Asia and the
Middle East. We also regained
commercial rights from
STADA to AVT06 pursuant
to this agreement. |
| · | We are also developing
through an in-license agreement
with Kashiv Biosciences
LLC, AVT23, a biosimilar
candidate to Xolair (omalizumab).
The agreement covers all
27 countries of the European
Union, the UK, Australia,
Canada, and New Zealand. |
| | | |
| · | Our pre-clinical programs
include AVT16, a biosimilar
candidate to Entyvio (vedolizumab),
AVT33, a biosimilar candidate
to Keytruda (pembrolizumab),
and three undisclosed programs.
|
Recent Developments
Financial
Updates
Sale
of shares
On
February 26, 2024, we announced that we had accepted an offer from investors to sell 10,127,132 of our ordinary shares at a $16.41
per share, for gross proceeds of approximately $166 million. The shares were delivered to the investors from the shares held in
treasury by our subsidiary, Alvotech Manco ehf., through the Nasdaq Iceland Main Market.
New term loan
credit agreement
On
June 7, 2024, we entered into a secured term loan credit agreement (the “Loan Agreement”), by and among us, as borrower,
GLAS USA LLC, as administrative agent, GLAS Americas LLC, as collateral agent, and the lenders party thereto, which provides for
a term loan in an aggregate principal amount of $965.0 million (the “Term Loan”). The Term Loan is scheduled to mature
on the fifth anniversary of the closing date.
Commercial
Updates
Agreement
with Quallent
In
April 2024, we and our partner Teva announced a long-term agreement with Quallent Pharmaceuticals LLC (“Quallent”)
to distribute AVT02 in the United States. Under a partnership agreement, we will manufacture AVT02 and Quallent will – distribute
the product under its own private label.
Agreement
with Dr. Reddy
In
May 2024, we announced that we had entered into a license and supply agreement with Dr. Reddy’s Laboratories SA for the commercialization
of AVT03. We will be responsible for development and manufacturing of the product. Dr. Reddy’s will be responsible for registration
and commercialization of the product in the applicable markets. The license and supply agreement includes an upfront payment to
us, with additional payments upon certain regulatory and commercialization milestones as well as sales-based payments, if AVT03
is approved. Dr. Reddy’s commercialization rights are exclusive for the United States, and semi-exclusive for the European
Economic Area (excluding Iceland), the United Kingdom and Switzerland.
Agreement
with STADA
In
June 2024, we announced that we had entered into an agreement with STADA to amend and strengthen our strategic partnership. Under
the terms of the agreement, we will be responsible for development and manufacturing AVT03 in Reykjavik, Iceland, and STADA will
become marketing authorization holder, upon approval of AVT03, and will assume semi-exclusive commercial rights in Europe, including
Switzerland and the UK, as well as exclusive commercial rights in selected countries in Central Asia and the Middle East.
In
parallel with the commercial agreement for AVT03, we agreed to extend STADA’s commercial rights to AVT02 and AVT04 to Commonwealth
of Independent States (CIS) countries in Central Asia, and we regained commercial rights from STADA to AVT06.
Financial Results for First Three Months
of 2024
The following discussion and analysis of Alvotech’s
financial condition and results of operations should be read in conjunction with Alvotech’s unaudited condensed consolidated interim
financial statements and related notes and other financial information that are included elsewhere in this filing, as well as our audited
consolidated financial statements and the related notes for the year ended 31 December 2023 and other financial information included in
the Company’s annual report on the Form 20-F filed on 20 March 2024. The following discussion is based on Alvotech’s financial
information prepared in accordance with the International Financial Reporting Standards, or IFRS, as issued by the International Accounting
Standards Board, or IASB. Some of the information contained in this discussion and analysis, including information with respect to Alvotech’s
plans and strategy for its business and related financing, includes forward-looking statements that involve risks and uncertainties. Alvotech’s
actual results could differ materially from the results described in or implied by the forward-looking statements contained in the following
discussion and analysis. All amounts discussed are in U.S. dollars, unless otherwise indicated.
Cash position and sources of liquidity:
As of March 31, 2024, the Company had cash and cash equivalents of $64.8 million, excluding $25.0 million of restricted cash. In
addition, the Company
had borrowings of $978.1 million, including
$37.6 million of current portion of borrowings, as of March 31, 2024.
Product Revenue: Product revenue
was $12.4 million for the three months ended March 31, 2024, compared to $15.7 million for the same three months of 2023. Revenue
for the three months ended March 31, 2024, consisted of product revenue from sales of AVT02 in select European countries and Canada,
launch of AVT02 in the U.S and launch of AVT04 in Canada.
License and Other Revenue: License
and other revenue was $24.4 million for the three months ended March 31, 2024. No license and other revenue were recognized during
the first three months ended March 31, 2023. The license and other revenue of $24.4 million was primarily attributable to the recognition
of a $6.5 million research and development milestone due to the approval of AVT04 in Europe and $16.8 million relative to research
and development milestone due to the CTA submission for the AVT16 clinical program.
Cost of product revenue: Cost of
product revenue was $20.0 million for the three months ended March 31, 2024, compared to $39.1 million for the same three months
of 2023, as a result of sales in the period, including the launch of AVT04 in Canada, tempered by lower production-related charges
and other costs associated with FDA inspection readiness. Cost of product revenue for the period is disproportionate relative to
product revenue due to the timing of new launches and elevated production-related charges, resulting in higher costs than revenues
recognized for the period. The Company expects this relationship to continue normalizing with increased production from the scaling
and expansion of new or recent launches. The Company estimates that the anticipated increase in sales volumes will result in a
greater absorption of fixed manufacturing costs.
Research and development (R&D) expenses:
R&D expenses were $49.9 million for the three months ended March 31, 2024, compared to $50.9 million for the same three months
of 2023. The slight decrease was primarily driven by a one-time charge of $18.5 million relating to the termination of the co-development
agreement with Biosana for AVT23 recognized during the three months of 2023, and a $17.8 million increase in direct program expenses
mainly from five biosimilar candidates, AVT03, AVT05, AVT06, AVT16 and AVT23 that are in clinical phase.
General and administrative (G&A)
expenses: G&A expenses were $15.5 million for the three months ended March 31, 2024, compared to $22.2 million for the
same three months of 2023. The decrease in G&A expenses was primarily attributable to $3.7 million in lower 3rd party services,
lower insurance premiums and less headcount, coupled with a $1.9 million decrease in expenses for share-based payments.
Finance income: Finance income was
$0.8 million for the three months ended March 31, 2024, compared to $1.2 million for the same three months of 2023. This was primarily
attributable to interests received on bank accounts resulting from lower cash balances versus the same period in the prior year.
Finance costs: Finance costs were
$184.1 million for the three months ended March 31, 2024, compared to $207.6 million for the same three months of 2023. The decrease
was primarily attributable to lower fair value of derivative liabilities from $179.1 million for the three months
ended March 31, 2023, to $140.9 million
for the three months ended March 31, 2024, partially offset by an increase in interest charged on additional borrowings and convertible
bonds issued during 2023.
Exchange rate differences: Exchange
rate differences resulted in a gain of $6.5 million for the three months ended March 31, 2024, compared to a loss of $1.7 million
for the same three months of 2023. The increase was primarily driven by the movements in the exchange rate of foreign currencies,
predominantly Icelandic krona and euros.
Income tax benefit: Income tax benefit
was $6.4 million for the three months ended March 31, 2024, compared to $29.4 million for the same three months of 2023. The decrease
was mainly driven by a decrease in operating losses and an unfavorable foreign currency translation effect during the three months
ended March 31, 2024 due to the weakening of the Icelandic krona against the U.S. dollar.
Loss for the Period: Reported net
loss was $218.7 million, or ($0.89) per share on a basic and diluted basis, for the three months ended March 31, 2024, compared
to a reported net loss of $276.2 million, or ($1.24) per share on a basic and diluted basis, for the same three months of 2023.
As mentioned above, the net loss for the period is heavily impacted by the fair value costs associated with our derivative liabilities.
| Unaudited Condensed Consolidated Interim Statements of Profit or Loss and Other Comprehensive Income or Loss |
| |
|
|
|
|
| |
|
|
|
|
| |
|
Three months ended
March 31, 2024 |
|
Three months ended
March 31, 2023 |
| |
|
|
|
|
| USD in thousands, except for per share amounts |
|
|
|
|
| |
|
|
|
|
| Product revenue |
|
12,430 |
|
15,864 |
| License and other revenue |
|
24,422 |
|
- |
| Other income |
|
42 |
|
19 |
| Cost of product revenue |
|
(19,957) |
|
(39,095) |
| Research and development expenses |
|
(49,868) |
|
(50,864) |
| General and administrative expenses |
|
(15,488) |
|
(22,198) |
| |
|
|
|
|
| Operating loss |
|
(48,419) |
|
(96,274) |
| |
|
|
|
|
| Share of net loss of joint venture |
|
- |
|
(1,164) |
| Finance income |
|
783 |
|
1,226 |
| Finance costs |
|
(184,063) |
|
(207,600) |
| Exchange rate differences |
|
6,532 |
|
(1,748) |
| |
|
|
|
|
| Non-operating loss |
|
(176,748) |
|
(209,286) |
| |
|
|
|
|
| Loss before taxes |
|
(225,167) |
|
(305,560) |
| Income tax benefit |
|
6,438 |
|
29,380 |
| |
|
|
|
|
| Loss for the period |
|
(218,729) |
|
(276,180) |
| |
|
|
|
|
| Other comprehensive loss |
|
|
|
|
| Item that will be reclassified to profit or loss in subsequent periods: |
|
|
|
|
| Exchange rate differences on translation of foreign operations |
|
(820) |
|
648 |
| Total comprehensive loss |
|
(219,549) |
|
(275,532) |
| |
|
|
|
|
| Loss per share |
|
|
|
|
| Basic and diluted loss for the year per share |
|
(0.89) |
|
(1.24) |
| Unaudited Condensed Consolidated Interim Statement of
Financial Position |
| |
|
|
|
|
| |
|
|
|
|
| USD in thousands |
|
31 March
2024 |
|
31 December
2023 |
| |
|
|
|
|
| Non-current assets |
|
|
|
|
| Property, plant and equipment |
|
235,394 |
|
236,779 |
| Right-of-use assets |
|
127,440 |
|
119,802 |
| Goodwill |
|
11,779 |
|
12,058 |
| Other intangible assets |
|
19,370 |
|
19,076 |
| Contract assets |
|
10,356 |
|
10,856 |
| Investment in joint venture |
|
18,494 |
|
18,494 |
| Other long-term assets |
|
2,285 |
|
2,244 |
| Restricted cash |
|
25,000 |
|
26,132 |
| Deferred tax assets |
|
318,223 |
|
309,807 |
| |
|
|
|
|
| Total non-current assets |
|
768,341 |
|
755,248 |
| |
|
|
|
|
| Current assets |
|
|
|
|
| Inventories |
|
92,236 |
|
74,433 |
| Trade receivables |
|
41,252 |
|
41,292 |
| Contract assets |
|
30,059 |
|
35,193 |
| Other current assets |
|
62,900 |
|
31,871 |
| Receivables from related parties |
|
1,038 |
|
896 |
| Cash and cash equivalents |
|
64,811 |
|
11,157 |
| |
|
|
|
|
| Total current assets |
|
292,296 |
|
194,842 |
| |
|
|
|
|
| Total assets |
|
1,060,637 |
|
950,090 |
| Unaudited Condensed Consolidated Interim Statement of Financial Position |
| |
|
|
|
|
| |
|
|
|
|
| USD in thousands |
|
31 March
2024 |
|
31 December
2023 |
| |
|
|
|
|
| Equity |
|
|
|
|
| Share capital |
|
2,604 |
|
2,279 |
| Share premium |
|
1,726,610 |
|
1,229,690 |
| Other reserves |
|
38,883 |
|
42,911 |
| Translation reserve |
|
(2,348) |
|
(1,528) |
| Accumulated deficit |
|
(2,424,574) |
|
(2,205,845) |
| |
|
|
|
|
| Total equity |
|
(658,825) |
|
(932,493) |
| |
|
|
|
|
| Non-current liabilities |
|
|
|
|
| Borrowings |
|
940,593 |
|
922,134 |
| Derivative financial liabilities |
|
330,976 |
|
520,553 |
| Lease liabilities |
|
110,585 |
|
105,632 |
| Contract liabilities |
|
88,913 |
|
73,261 |
| Deferred tax liability |
|
1,610 |
|
53 |
| |
|
|
|
|
| Total non-current liabilities |
|
1,472,677 |
|
1,621,633 |
| |
|
|
|
|
| Current liabilities |
|
|
|
|
| Trade and other payables |
|
50,175 |
|
80,563 |
| Lease liabilities |
|
11,161 |
|
9,683 |
| Current maturities of borrowings |
|
37,550 |
|
38,025 |
| Liabilities to related parties |
|
24,532 |
|
9,851 |
| Contract liabilities |
|
46,258 |
|
59,183 |
| Taxes payable |
|
1,096 |
|
925 |
| Other current liabilities |
|
76,013 |
|
62,720 |
| |
|
|
|
|
| Total current liabilities |
|
246,785 |
|
260,950 |
| Total liabilities |
|
1,719,462 |
|
1,882,583 |
| |
|
|
|
|
| Total equity and liabilities |
|
1,060,637 |
|
950,090 |
| Unaudited Condensed Consolidated Interim Statements of Cash Flows |
| |
|
|
|
|
| USD in thousands |
|
Three months ended
March 31, 2024 |
|
Three months ended
March 31, 2023 |
| |
|
|
|
|
| Cash flows from operating activities |
|
|
|
|
| Loss for the year |
|
(218,729) |
|
(276,180) |
| Adjustments for non-cash items: |
|
|
|
|
| Long-term incentive plan expense |
|
- |
|
6,449 |
| Depreciation and amortization |
|
7,190 |
|
4,841 |
| Change in allowance for receivables |
|
- |
|
18,500 |
| Change in inventory reserves |
|
(5,379) |
|
- |
| Share of net loss of joint venture |
|
- |
|
1,164 |
| Finance income |
|
(783) |
|
(1,226) |
| Finance costs |
|
184,063 |
|
207,600 |
| Share-based payments |
|
2,828 |
|
- |
| Exchange rate difference |
|
(6,532) |
|
1,748 |
| Income tax benefit |
|
(6,438) |
|
(29,380) |
| |
|
|
|
|
| Operating cash flow before movement in working capital |
|
(43,780) |
|
(66,484) |
| Increase in inventories |
|
(12,424) |
|
(3,766) |
| Increase in trade receivables |
|
40 |
|
2,952 |
| Increase / (decrease) in liabilities with related parties |
|
14,539 |
|
(573) |
| (Increase) / decrease in contract assets |
|
5,634 |
|
895 |
| Increase in other assets |
|
(2,959) |
|
5,246 |
| Increase in trade and other payables |
|
(28,927) |
|
(18,600) |
| Increase in contract liabilities |
|
4,176 |
|
616 |
| (Decrease) / increase in other liabilities |
|
(7,139) |
|
(4,477) |
| |
|
|
|
|
| Cash used in operations |
|
(70,840) |
|
(84,191) |
| Interest received |
|
26 |
|
21 |
| Interest paid |
|
(4,403) |
|
(1,845) |
| Income tax paid |
|
(186) |
|
(116) |
| |
|
|
|
|
| Net cash used in operating activities |
|
(75,403) |
|
(86,131) |
| Cash flows from investing activities |
|
|
|
|
| Acquisition of property, plant and equipment |
|
(4,069) |
|
(11,327) |
| Acquisition of intangible assets |
|
(543) |
|
(2,548) |
| Restricted cash in connection with amended bond agreement |
|
1,132 |
|
- |
| |
|
|
|
|
| Net cash used in investing activities |
|
(3,480) |
|
(13,875) |
| |
|
|
|
|
| Cash flows from financing activities |
|
|
|
|
| Repayments of borrowings |
|
(1,629) |
|
(50,812) |
| Repayments of principal portion of lease liabilities |
|
(2,338) |
|
(1,525) |
| Proceeds from new borrowings |
|
- |
|
60,421 |
| Gross proceeds from equity offering |
|
138,049 |
|
136,879 |
| Fees from equity offering |
|
(5,743) |
|
(4,141) |
| Proceeds from warrants |
|
4,841 |
|
6,365 |
| |
|
|
|
|
| Net cash generated from financing activities |
|
133,180 |
|
147,187 |
| |
|
|
|
|
| Decrease in cash and cash equivalents |
|
54,297 |
|
47,181 |
| Cash and cash equivalents at the beginning of the period |
|
11,157 |
|
66,427 |
| Effect of movements in exchange rates on cash held |
|
(643) |
|
2,236 |
| |
|
|
|
|
| Cash and cash equivalents at the end of the period |
|
64,811 |
|
115,844 |
Alvontech (NASDAQ:ALVOW)
Historical Stock Chart
From Nov 2024 to Dec 2024
Alvontech (NASDAQ:ALVOW)
Historical Stock Chart
From Dec 2023 to Dec 2024
